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To my dearest parents 
�tfifta{J'i;{.,A. 
STELLING EN 
behorend bij het proefschrift 
Molecular Remodeling in Atrial Fibrillation: Protective Roles of Small HSPs 
Lei Ke 
I. Calpain activation represents a key factor underlying cardiac troponin degradation, myolysis 
and contractile dysfunction in atrial fibrillation. (This thesis) 
2. The Rho pathway plays a prime role in the reduction of calcium transients and induction of 
atrial fibrillation. (This thesis) 
3. The chaperone-like activity of small heat shock proteins is not of prime importance for their 
protective role on molecular remodeling in atrial fibrillation. (This thesis) 
4. Every disease is a physician. (Irish Proverb) 
5. Maintenance of sinus rhythm (rhythm control) appears preferable for the treatment of atrial 
fibrillation. However, studies to date have failed to demonstrate tangible advantages of 
rhythm control. (Dobrev and Nattel Cardiovascular Research (20 //) 89, 689-691) 
6. I am sure that even the simplest cell is still more delicate than a super-computer. (Zhai 
Zhonghe, translatedfrom "it!ldff{f!J/Jffl-1'-Jl:fn,._,P.fl(Jf!f/Jj(ff, tElt:@4-.:XJJ.f:ifli/-!:iJl!(Jf:Efllf 
!Jffjg,:/3/JiJi.ff!!!fl}"'' -l/!,P,f/1) 
7. The purpose of original research is to make a meaningful contribution to knowledge, rather 
than to identify niches where "original" work can be done. 
8. Imitate it until you have it. 
9. While Dutch claim to be "gezellig", this is certainly not substantiated by their behavior in 
trains, where they spread their luggage on the nearby seats, thus preventing anybody to sit 
next to them. 
10. Life moves pretty fast. If you don't stop and look around once in a while, you could miss it. 
(Ferris Buel/er) 
I I. AtEi\tiimAt, ¥�:tjtJ-ls: AtEf�iimA-L ¥�A�Eo CJ,VJUID Life's ups provide one with 
self-esteem, but life's downs provide one with the cherished love from friends and family. 
12. No one realizes how beautiful it is to travel until he comes home and rests his head on his old, 
familiar pillow. (Lin Yutang) 
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CHAPTER I 
General Introduction and Scope of Thesis 
Chapter 1 
1. Atrial Fibrillation 
Atrial Fibrillation (AF) is the most common sustained and progressive clinical arrythmia 
and a significant contributor to cardiovascular morbidity and mortality (1). In the healthy 
heart, the normal electrical impulses generated by auto-rhythmic cells of the sinus node 
travel through the two upper chambers (atria) of the heart and reach towards the 
ventricles via the purkinje fibers through the atria-ventricular node (AV node). At rest, the 
normal impulses lead to the heartbeats at a typical rate of about 60-70 beats per minute 
(bpm), whereas they can reach up to 180-200 bpm during heavy exercise. In AF, the 
normal electrical impulses are overwhelmed by disorganized and much faster electrical 
impulses ( 400-600 bpm) that derive from the atria and pulmonary veins, leading to atrial 
quivering or fibrillating instead of atrial contraction. Thanks to the limited conductive 
capacity of AV node, only about a third of these irregular impulses are transferred to the 
ventricles that generate the increased heartbeat of about 100-200 bpm (1 ). 
The irregular heartbeats may occur in episodes lasting from minutes to weeks, or they 
could occur all the time for years. The natural tendency of AF is to become more 
persistent over time (2). In many cases, AF may be asymptomatic and a patient for the 
first time becomes aware from a routine physical examination or electrocardiogram 
(ECG). AF usually results in symptoms related to a rapid heartbeat, like light-headedness, 
palpitations, chest discomfort. Occasionally, rapid and irregular heartbeats may also be 
perceived as angina, shortness of breath or edema. Furthermore with longer AF existence, 
it develops to other severe cardiovascular problems, such as chronic heart failure (CHF), 
stroke, thromboemboli or infarction (1, 3). 
In some cases, AF, as a second condition, is associated with a variety of primary 
conditions, such as hypertension, cardiac surgery, pericarditis, congestive/coronary heart 
failure, congenital heart disease, pneumonia or other acute pulmonary disease. These 
primary conditions may be the cause of the AF (3, 4). 
In about 30% of AF, patients are absent with any clinical or ECG findings of other 
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cardiovascular disease, cardiac abnormalities or related pulmonary disease. In these cases, 
it is called "lone AF". Some argued that it might be caused by other risk factors, including 
alcohol abuse, obesity, metabolic syndrome, psychological stress or even genetic factors 
(5 -7). 
Based on episode timing and termination, AF can be divided into four categories: I)first 
detected AF, in which all AF patients are initially included; 2) Paroxysmal AF occurring 
in episodes that terminate spontaneously and generally lasts less than or equal to 7 days 
(mostly less than 24 hours). 3) If AF lasts more than 7 days, it is unlikely to terminate 
spontaneously but can be converted to sinus rhythm by cardioversion. This stage is called 
persistent AF. 4) If cardioversion is unsuccessful or deemed unnecessary, AF is ongoing 
for a long time and called as permanent AF (3). Persistent and permanent AF are also 
referred to as chronic AF (CAF) (3). 
2. Basic Mechanisms of AF Initiation 
Over the past decade, great advance has been made in the understanding of mechanisms 
for AF initiation. At the present time, two hypotheses predominate to explain AF 
initiation ( 1, 8): 
a) ectopic activity: While the rate of atrial cell firing is faster than that of sinus node, 
ectopic activity occurs. Pulmonary veins (PV s) may also act as sources of ectopic activity 
for AF (9). Any factors that contribute to premature depolarization (the accelerated slope 
of phase 4) would cause the increased spontaneous rate and therefore leads to ectopic 
activity. 
b) Reentry: In this mechanism, wavelet reentry produces either single or multiple atrial 
circuits that may each meander, interact or extinguish. To better understand this 
mechanism, the useful concept "wavelength" is worthwhile to be mentioned. The 
"wavelength" is defined as the distance traveled by an impulse within one effective 
refractory period (ERP) and so determined by the product of ERP duration and 
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conduction speed at which the impulse travels through the atrial tissue. For reentry to be 
maintained, the impulse must traverse all points of the entire circuit only if it falls outside 
the ERP at each point. Otherwise the wavelet reentry would extinguish. The wavelength 
approximates the shortest path length of reentry and therefore determines the size of 
maintainable reentry circuit. 
When the wavelength of the electrical impulse is relatively greater, the impulse travels 
slowly enough through the whole atrial tissue in a manner of single circular way. Multiple 
circuit reentry works in a similar way to single circuit re-entry, but in this case a shorter 
wavelength will require the shorter minimum path length of individual circuits, and 
therefore allows more circuits to occur at the same time. In this manner, the likelihood for 
spontaneous termination of the multiple circuit reentry would be reduced and thus AF 
would be easier maintained. 
In conclusion, any factors relating to the mechanisms described above would contribute 
to AF initiation and the subsequent remodeling would furthermore augment the 
probability of AF maintenance and progression. 
3. Atrial Remodeling 
The concept "atrial remodeling" defines any change in atrial structure or function that 
promotes atrial arrhythmogenesis. The concept was prompted by early clinical 
observations: many patients were seen to transit from increasingly frequent and longer 
paroxysmal AF to persistent AF, until permanent AF eventually ensued. The longer AF 
persists, the more difficult it becomes to maintain sinus rhythm after cardioversion 
( l 0, 11 ). The changes in atrial tissue can be divided into two principal forms: 
tachycardia-induced remodeling and structural remodeling. 
3.1. Tachycardia-induced remodeling 
In Wijffels' pioneering work, he found that AF itself was the cause of the abnormal 
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electrophysiologic properties, which could in tum promote the recurrence and 
maintenance of AF. The phenomenon is also referred to as electrical remodeling and 
described as "AF begets AF" (12). The rationale for the self-promoting nature of AF is 
that tachycardia induces a reduction of ERP and the reduced ERP leads to the decreased 
wavelength promoting wavelet reentry and the recurrence/maintenance of AF. 
To understand the rationale, it is important to look at the ionic basis of cardiac action 
potential. At the physiological status, the membrane potential of atrial myocytes remains 
around-70 mV at rest. Once the cell is electrically stimulated, the opening of the fast Na+ 
channel and the rapid influx of Na+ into cells trigger a depolarization of the cell 
membrane potential up to +30 mV. When the cell membrane potential is positive, the fast 
Na+ channel is inactivated. At that moment, the transient net outward K+ ions through the 
transient outward K+ channels 010) cause a brief downward deflection of the action 
potential. In the meanwhile, the inward movement of Ca2+ through L-type calcium 
channels OcaL), balanced with the outward movement of the slow delayed rectifier 
potassium channels OKs), leads to the plateau stage of cardiac action potential. The 
sodium-calcium exchanger current 0Na-ca) and sodium/potassium pump current 0Na-K) 
also play minor roles during this phase. When L-type Ca2+ channels close, the slow 
delayed rectifier potassium channels OKs) is still open and ensure negative change in 
membrane potential. Under this circumstance, the rapid delayed rectifier potassium 
channels 0Kr) are open and cause the cell to reploarize (13). 
3.1.1. Tachycardia-induced changes in Ca2+ handling 
With the onset of tachycardia, the rapid and irregular atrial rates substantially causes 
intracellar Ca2+ overload in atrial myocytes (14). Due to the fact that Ca2+ overload is 
cytotoxic, atrial myoctyes respond by reducing the amount of Ca2+ entering into cells via 
L-type Ca2+ channels. The influx of Ca2+ is a major contributor to the "plateau" phase of 
cardiac action potential, and thus the tachycardia-induced reduction of Ca2+ transient 
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leads to decreased action potential duration (APD) favoring AF recurrence and 
maintenance (8). 
In the early stage of response, the reduction of Ca2+ transient occurs because of functional 
inactivation of L type Ca2+ channels. The functional inactivation is dependent on the 
voltage of cell membrane potential and Ca2+ concentration in atrial myocytes (15). In this 
manner, APD can be affected as quickly as 7 minutes after the induction of tachycardia in 
humans ( 16). 
When tachycardia sustains, Ca2+ transient is persistently reduced via activation of the 
Ca(2+)-dependent calmodulin-calcineurin-NFAT system to cause transcriptional 
downregulation of calcium L-type channel protein subunits (17). For the a 1 subunit of 
calcium L-type channel protein, the downregulation was observed both at the mRNA and 
protein level (18-20) and at posttranslational steps such as protein dephosphorylation and 
proteolysis (21, 22). In addition, the use of calpain inhibitor in an in vitro model of AF 
attenuated the breakdown of L-type Ca2+ channel protein (23). In a rabbit model, 
researchers have also detected the reduced expression of all three �-subunits, which also 
suggests an important role of L-type Ca2+ channel protein in tachycardia-induced 
remodeling (24 ). 
3.1.2. Tachycardia-induced changes in other ion channels 
Transient outward K+ current Oto) has been seen to decrease both in animal models (24,25 ) 
and in AF patients (26,27). Decreased Ito is associated with the observation that both 
mRNA and protein expression of its subunit K v4.3 showed the reduction ( 18). The 
breakdown of protein subunit Kv4.3 may be mediated by the increased calpain activity 
(22,28). The decreased expression of K v4.3 mRNA may be contributed by 
Ca2+ -dependent protein phosphatase calcineurin (29), since an increased activity of 
calcineurin was reported in human AF (30). Ito counters with inward Na
+ current during 
the phase 1 of action potential, and thus the downregulation of Ito increases the action 
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potential amplitude. However, the functional implication of 110 downregulation is unclear 
in AF setting (8). 
The delayed-rectifier current Ikr and lks are not changed in experimental model of atrial 
tachycardia (25), and the information from AF patients is lacking. 
3.2. Atrial structural remodeling 
If tachycardia-induced remodeling progresses, the atrial structural remodeling will occur 
resembling hibernation, which creates a further promoting substrate for AF perpetuation 
(22,31,32). Hibernation is a form of tissue adaptation which resembles ischemic 
hibernation and is defined as the ability of the myocytes to tum into a non-functional 
phenotype by degradation of the myofibril structure (myolysis), which leads to contractile 
dysfunction (31,33-35). Other characteristics are redistribution of nuclear chromatin, loss 
of sarcoplasmic reticulum, increase in abnormal shaped mitochondria and increase in 
glycogen accumulation. Interestingly, no profound imbalance in energy status during 
chronic AF was observed (36). Degenerative changes are not observed, but instead atrial 
myocytes shift towards a fetal phenotype (dedifferentiation). Cell viability will, however, 
be maintained for a prolonged period of time, thus ensuring tissue integrity (but not tissue 
functionality) (34). Consequently, myolysis is found in patients with persistent AF and 
not in patients with exclusively displaying paroxysmal forms of the arrhythmia (22), 
suggesting a role for myolysis in the progression of AF. 
Atrial structural remodeling also happens as a result of other cardiovascular diseases 
underlying AF, like heart failure. In Morillo's pioneering study, AF-associated 
ultrastructural changes in atrial myocytes were first reported (37). These structural 
changes of atrial myocytes resemble the alterations in ventrical myocytes occurring after 
ischemia (ischemic hibernation) (38,39). Myocytes with hibernation caused by 
tachycardia or AF are thought to remain viable, ensuring tissue integrity, but loose their 
contractile function, which may explain the function of myocytes is still impaired even 
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after cardioversion of AF (33-35 ). 
In animal models, AF-associated structural remodeling includes increase in cell size 
(hypertrophy), myolysis (loss of myofibrils), changes in quantity and localization of 
structural cellular proteins, homogeneous distribution of nuclear chromatin as in fetal 
cells ( dedifferentiation), altered connexin expression, fragmentation of sarcoplasmic 
reticulum, change in mitochodrial shape and size, accumulation of glycogen (31,40). 
In AF patients, similar changes were found (22,41,42), however some degenerative 
features were also observed. The myocytes from patients with AF and atrial dilation 
showed signs of DNA cleavage and programmed cell death (43). These broader structural 
changes than in animal models was suggested to relate to the older age and/or associated 
heart diseases ( 40). 
The exact mechanisms underlying the various structural alterations relating to AF are not 
fully known yet. The electrical remodeling is completely recovered within a few days 
even after prolonged AF (32,44). On the contrary, myolysis, the most prominent change 
in AF, was still seen in many atrial myocytes even after 16 weeks of sinus rhythm, 
suggesting AF-related structural changes are difficult to be reversible ( 41 ). The activation 
of cystein protease seems one of the principal components linking AF-related electrical 
remodeling and structural remodeling (22,23). 
4. Heat shock proteins in AF 
4.1. Heat shock proteins and cardioprection 
It has been recognized that AF induces cardiomyocyte stress. Since induction of the heat 
shock response provides cytoprotective effects that may be beneficial in a variety of acute 
diseases ( 45), including major cardiac disorders ( 46), it was hypothesized that a heat 
shock response might also be benificial in AF. There are at least five main heat shock 
protein (HSP) families, small Hsp (HSPB), Hsp40 (DNAJ), HSP60 (HSPD), Hsp70 
(HSPA), and Hsp90 (HSPC), each with several family members, (specific) co-factors in 
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various cellular localizations and distinct and overlapping functions (47,48). These highly 
conserved proteins have important roles in protein folding, trafficking and cell signaling 
(47,49,50). 
A substantial literature described the induction of HSPAIA (Hsp70) by ischemia and 
inverse correlation between expression of HSPAIA and infarct size in animal models 
(46). In addition, overexpression of HSPAIA offers a cytoprotective effects in cardiac 
myocytes subjected to simulated ischemia, improves myocardial function in animal 
models with ischemia, preserves metabolic functional recovery, and reduces infarct size 
after ischemia/reperfusion (46). Besides HSPAIA, also HSPBI (Hsp27) and HSPB5 
(alpha B-crystallin) can protect primary cardiomyocytes against ischemic damage (46). 
Although the precise mechanisms are insufficiently understood, HSPs are thought to 
mediate these cardioprotective effects in ischemic diseases through their biological 
functions as molecular chaperones. In vitro overexpression of the small Hsp family 
member HSPB I enhances alpha-actinin and F-actin stability and recovery after disruption 
(51, 52). The stress-inducible HSPAIA binds and protects the microtubule network and 
therefore limits myofibril disruption after ischemic stress in myocardium (53). These 
observations suggest that HSPBl and/or HSPAIA might have a protective effect in 
AF-induced structural remodeling. 
4.2. Heat shock proteins and AF 
The conventional therapeutic approach, the use of antiarrhythmic drugs, has been proven 
to have side effects on the electrophysiology of the ventricles, in such a way that they can 
paradoxically cause arrhythmic disorders and increase mortality (54). Recently, a detailed 
summary of pharmacological approaches to prevent atrial remodeling and their efficacy 
were extensively discussed (5 5 ). Rather than preventing arrhythmia, another approach 
could be used to make cells resistant to AF-stress and prevent the early triggers for 
remodeling and therefore more permanent structural remodeling. Hereto, HSPs might 
come into play. Many HSP can act as molecular chaperones and hereby were shown to be 
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able to protect cells against various forms of proteotoxic damage. Indeed, HSPs were 
found to play a protective role in various cardiovascular diseases (Table 1 ). 
Table 1. Major stress proteins and their protective roles in cardiac diseases. 
Stress Previous Approx. number of Protective Cardiac References 
protein family name human family members Member Disease 
HspA Hsp70 1 5* HspAlA Ischemic heart (56,57) 
disease 
DNAJ Hsp40 >40* DNAJA3 Dilated (58) 
cardiomyopathy 
HspB Small Hsp 1 0  HspB l Atrial (59) 
(Hsp27) Fibril lation 
Ischemic heart (60,6 1 ) 
disease 
HspB5 (Dilated) (62,63) 
(aBCrystall in) Cardiomyopathy 
HspB6 Ischemic heart (64) 
(Hsp20) disease 
HspD Hsp60 8* HspDl Heart failure (65) 
(Hsp60) 
HspC Hsp90 8* HspCA Ischemic heart (66) 
(Hsp90) disease 
*= includes possible pseudogenes. 
Two studies reported elevated expression of mitochondrial HSPs, specifically HSPD I 
(67), HSPE I and mortalin (HSPA9B) in atrial tissue from patients with AF (68). HSPDI 
and HSPE I form a mitochondrial chaperonin complex, and a previous study has shown 
that their increased expression exerts a protective effect against injury when cardiac 
myocytes are submitted to ischaemia (69). Also in AF, the up-regulation of these 
mitochondrial chaperonins (HSPD I and HSPE 1) in combination or individually may play 
a role in the endogenous response to AF and by maintaining mitochondrial integrity and 
capacity for ATP generation, they could form crucial factors in determining survival of 
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cardiac myocytes during AF. However, besides induction of HSPDI, HSPEI and 
HSPA9B (67,68) also a reduction of HSPDI (70) has been reported as response to AF. 
Thus, whether mitochondrial Hsp indeed play a role in AF remains to be determined. To 
date, no systematic studies to ectopically up-regulate their expression before or during AF 
have been performed to more conclusively address this hypothesis. 
Both Rammos et al. (71) and Mandal et al. (72) studied HSPAIA expression levels in 
atrial tissue of patients in sinus rhythm undergoing cardiac surgery. Both studies 
consistently showed a lower incidence of post-operative AF in patients with higher atrial 
HSPAIA expression levels. A recent study in atrial fibroblasts from rats showed 
HSPAIA, induced by a general heat shock, could be involved in the prevention of 
angiotensin II mediated atrial fibrosis and increased atrial vulnerability to extrastimuli 
(73). Whereas this suggest that HSPAIA may be involved in prevention of AF initiation, 
the role of HSPAIA on AF promotion (measured as duration of induced AF) and AF 
vulnerability (percentage of sites at which AF was induced by single premature stimuli) 
were not studied. In fact, studies from our own lab with an in vitro AF model using paced 
mouse cardiomyocytes suggested that HSPAIA did not prevent structural remodeling. 
Rather, these data suggested a role for small HSPB proteins in preventing AF-mediated 
structural remodeling (59). Therefore the focus of this thesis will be on the role of HSPB 
proteins in AF 
4.3. Small heat shock proteins 
The family of small heat shock proteins (HSPB family) consists of at least IO members 
and they are expressed in various human tissues (Table 2). HSPB members are defined by 
a conserved C-terminal domain of ~90 amino acids (the a-crystallin domain) flanked by a 
variable length N-terminal arm and a more conserved C-terminal extension. It is thought 
at least some HSPB members assemble into homo-and/or heterogeneous oligomeric 
complexes, which dissociate into smaller multimers (74). Another important 
characteristic is that some HSPB members can be phosphorylated at certain sites to 
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regulate their activity, maybe by regulating the oligomeric state of the proteins. 
Table 2: Characteristics of small HSPB members (74). 
Gene Protein Alternative Sequence Molecular Heat Expression Other tissue 




HSPB1 HSPBl HSP27, 22.783 Yes +++ 
100% kidney, some 
HSP28 
tumor cells 
HSPB2 HSPB2 MKBP 36% 20.233 No + Skeletal muscle 
HSPB3 HSPB3 HSPL27 23% 16.966 + Skeletal muscle 
aA-crystall in, 
HSPB4 H SPB4 CRYAA, 19.909 No Lens of eye, spleen 
36% 
CRYAl 
Lens of eye, 
aB-crystallin, vascular wall cells, 
HSPBS HSPBS CRYAB, 20. 159 Yes ++++ lung, kidney, 
38% 




HSPB6 HSPB6 Hsp20, p20 34% 17. 136 No ++ 
lung, kidney, 
platelet 
HSPB7 HSPB7 cvHsp 20% 18.611 ? ++++++ Skeletal muscle 
Skeletal muscle, 
HSPBB HSPB8 Hsp22, H l l  34% 21.604 Yes ++ stomach, liver, 
lung, kidney, brain 
HSPB9 HSPB9 FU27437 19% 17.486 ? Testis 
HSPB1 
HSPBlO ODFl 17% 28.366 ? Testis 
There are at least three, not mutually exclusive, biochemical functions that have been 
ascribed to small Hsp. First, both cell free and cellular data have suggested that (some) 
HSPB members can act as ATP-independent chaperones believed to prevent irreversible 
protein aggregation. Oligomeric dynamics seems to be crucial for such HSPB activities 
(75). HSPB-clients may next be processed (renaturation or degradation) through 
1 8  
General Introduction and Scope of Thesis 
cooperation with ATP-dependent chaperones (76, 77). As such, stress-induced protein 
damage that could include AF-mediated remodeling, may be prevented. Second, several 
HSPB members were shown to be associated with cytoskeletal proteins in a 
phosphorylation dependent manner (78, 79). This may on one hand result in stabilization 
of certain cytoskeletal structures (78, 79), which - in tum - may be associated with 
increased resistance myofilament proteins against AF. On the other hand, some HSPB 
members were suggested to be involved in actin-reorganization (79), suggesting they may 
assist in recovery from AF-mediated myolysis. Finally, although biochemically poorly 
understood, HSPB members may inhibit the action of proteases (80) and as such may 
interfere with the cystein protease that seems to be activated upon AF. 
4.4. The diverse members of the HSPB family: functional similarities and divergence 
Beside the role of HSPB 1 in assisting in refolding and/or targeting denatured proteins, 
another well characterized function of HSPB I is its ability to interact with several 
cytoskeletal components, including actin, intermediate filaments, and microtubules (78). 
In muscle tissue, HSPB l is found in association with sarcomeres and suggested to be 
cardioprotective (59). 
HSPB2 is associated specifically with myotonic dystrophy protein kinase (DMPK) and 
also have been called a DMPK-binding protein (MKBP), suggesting its important role in 
muscle maintenance (81 ). During muscle differentiation, the 150-kDa complexes 
consisting of both HSPB2 and HSPB3 are induced, which suggest both HSPB3 and 
HSPB2 to play a role in muscle development (82). During ischemia, HSPB2 can 
translocate from cytosol to myofibrillar fraction, Z line, which suggests HSPB2 may offer 
protection against ischemia/reperfusion injury via binding to certain myofibrillar structure 
(83). 
HSPB4 ( a A-crystallin) and HSBP5 ( a B-crystallin) are both strongly expressed in the 
eye lens, where they together maintain lens transparency. Both proteins indeed have 
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chaperone-like activity in cell free systems (84) and in l iving cells (85 ) which may (in 
part) explain their function in the eye lens. In the heart, HSPB5 co-localizes in the I-band 
and M-line region of myofibrils in cardiomyocytes (86). HSPB5 is known to bind and 
stabilize myofibrillar proteins, including actin, desmin and titin (87,88). Some HSPB5 
mutants have been reported to be involved in myofibrillar myopathy and loss of ischemic 
protection (89). Like HSPBl , HSPB5 also plays an important role in stabilization of the 
cytoskeleton as it is expressed together with HSPB 1 to associate with sarcomeric 
structures (90). 
HSPB6 (HSPB20) is abundantly expressed in skeletal muscle and heart in two forms of 
complexs: 43-kDa dimers and 470-kDa multimers. HSPB6 has been shown to bind to 
itself and other sHsps (HSPB 1, B5 , B8) (91) and is trans located to the myofibrils in adult 
rat heart and skeletal muscle under ischemic conditions (92). Further evidence has 
demonstrated that HSPB6 binds to actin and actinin in vitro and in vivo, depending on its 
phosphorylation state (64,93). These findings suggest that HSPB6 may positively regulate 
heart function through stabilization of the cytoskeleton. Recently, it has been shown that 
HSPB6 overexpression resulted in significantly enhanced cardiac function by interacting 
with protein phosphatase-I and enhancing Ca2+ cycling and sarcoplasmic reticulum Ca2+ 
load (94). 
HSPB7, also known as cvHSP, is expressed in heart and skeletal muscle. Analysis of 
aging muscles shows a large increased level of expression of both HSPB7 and HSPB5 
(95 ). This could reflect a cellular adapation to higher-proteotoxic stress conditions related 
to muscle degeneration. HSPB7 upregulation is also found in muscular 
dystrophy-affected diaphragm muscle, again linking high stress levels with HSPB7 
induction. Furthermore, HSPB7 was recently shown to protect cells from protein 
aggregation, likely by facilitating cargo delivery to autophagosomes; yet unlike HSPB 1, 
HSPB4 or HSPB5 , HSPB7 could not enhance the cellular capacity to chaperone heat 
denatured luciferase, indicating further functional differentiation of the HSPB members 
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(85 ,96). 
HpsB8 (HSP22/Hll/E21Gl) is strongly expressed in striated and smooth muscles, brain, 
and keratinocytes. Like HSPB 1, HSPB5 and HSPB8 can also be phosphorylated in vitro. 
In contrast to HSPB 1 and HSPB5 , phosphorylation only marginally affects the tertiary 
and quaternary structure of HSPB8. Both wild-type and phosphorylated HSPB8 exist as 
low-molecular mass oligomers. Unlike HSPB 1 and HSPB5 where phosphorylation 
increase chaperone activity and reduce oligomeric size, phosphorylated HSPB8 shows a 
slightly larger oligomeric structure and severely lowered chaperone activity. In vitro, 
HSPB8 can form high-molecular mass hetero-oligomers with other members of HSPB 
family. In vivo, a stable and stoichiometric complex exists by binding with Bag3 and this 
association dramatically influences HSPB8 stability (97). In cells, HSPB8 complexes 
with a number of proteins; most specifically, it forms a stoichiometric complex with Bag3, 
a co-factor of the HSP70 (97). The Bag3/HSPB8 complex was recently shown be able to 
induce both translational arrest and autophagy (98,99), which may be relevant in the 
cellular response to irreparable protein damage. 
Next to the muscle-associated HSPB members, two members (HSPB9 and HSPB 10) are 
exclusively expressed in testis. 
5. Scope of thesis 
The main goal of this thesis was to get more insight in the proteolytic processes induced 
in cells undergoing pacing, to elucidate whether any member of the small HSPB family 
members may be able to protect against such AF-induced remodeling and, if so to 
elucidate their mechanisms of action. Hereto, we first characterized key endpoints for 
structural remodeling in the in vitro tachypaced HL-1 atrial cardiomyocyte model for AF 
(Chapter 2). Here, we investigated which myofibrillar cardiac troponin proteins are 
degraded in tachypaced HL-1 cardiomyocyte model and in atrial tissue of patients with 
AF. Furthermore, the proteases underlying troponin degradation were determined and we 
tested whether their inhibition leads to preservation of contractile function after AF. 
2 1  
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In Chapter 3, we next investigated if a general HSP upregulation (accomplished by mild 
heat shock/GGA drug treatment) can protect against AF-induced structural remodeling in 
a tachypaced cell model. In addition, transgenic overexpression of individual HSPs 
(HSPAI A and HSPBl ) was tested for a possible protective role in in vitro tachypaced 
HL-1 cardiomyocytes and in human AF. Here, we found that HSPB 1 rather than HSPA 1 A 
might have protective effects in AF. 
We therefore next compared all 10 HSPB members for their ability to protect against 
tachypacing-induced contractile dysfunction. Furthermore, among the protective HSPB 
members, the mechanism of action was determined (Chapter 4). 
In Chapter 5, we decided to extend our findings from a cell model to a multicellular 
models system. Hereto, we developed a Drosophila melanogaster model for AF-induced 
remodeling. After validation of the model and establishing that a general HSP induction 
also yields AF-protective effects in this in vivo model, we tested various HSPB 
overexpressing Drosophila strains for their resistance towards tachypacing-induced 
remodeling. 
Finally, in Chapter 6, we briefly summarized and discussed the data obtained in our 
experimental chapters and provide some future perspectives. 
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Abstract 
The self-perpetuation of atrial fibrillation (AF) is associated with atrial remodeling, 
including the degradation of the myofibril structure (myolysis). Myolysis is related to 
AF-induced activation of cysteine proteases and underlies loss of contractile function. In 
this study, we investigated which proteases are involved in the degradation of 
myofibrillar proteins during AF and whether their inhibition leads to preservation of 
contractile function after AF. In tachypaced HL-1 cardiomyocytes and atrial tissue from 
AF and control patients, degradation of myofibrillar proteins troponin (cTn) T, I, C, 
human cTnT and actin was investigated by Western blotting, and contractile function was 
analyzed by cell-shortening measurements. The role of major proteases was determined 
by applying specific inhibitors. Tachypacing of HL-1 cardiomyocytes induced a gradual 
and significant degradation of cTns but not actin, and caused contractile dysfunction. 
Both were prevented by inhibition of calpain but not by inhibition of caspases or the 
proteasome. In patients with persistent AF, a significant degradation of cTnT, cTnl and 
cTnC was found compared to sinus rhythm or paroxysmal AF, which correlated 
significantly with both calpain activity and the amount of myolysis. Additionally, by 
utilizing tachypaced human cTnT-transfected HL-1 cardiomyocytes, we directly showed 
that the degradation of human cTnT was mediated by calpain and not by caspases or 
proteasome. Our results suggest that calpain inhibition may therefore represent a key 
target in combating AF-related structural and functional remodeling. 
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Introduction 
Atrial Fibrillation (AF), the most common clinical tachyarrhythmia and an important 
contributor to cardiovascular morbidity and mortality (1 ), tends to become more 
persistent over time (2,3). The mechanisms underlying self-perpetuation are linked to 
rapid changes in electrical and contractile functions of cardiomyocytes. When the 
arrhythmia persists, AF induces changes at the structural level, predominantly myolysis 
( 4,5 ). Myolysis is characterized by loss of myofibril structure, leading to contractile 
dysfunction (6,7) and AF progression (4, 5 ). AF is accompanied by reduced expression 
levels of all three subunits of the myofibrillar troponin complex, cTnT, cTnl and cTnC 
(8,9), which is the main regulatory component of cardiac contraction in response to a rise 
of intracellular Ca2+ concentration (10). Therefore, identification of therapeutic 
approaches and mechanisms that stabilize the troponin complex during AF are important 
for the attenuation of AF-induced atrial remodeling. 
We previously showed increased activation of the Ca2+ -dependent neutral protease 
calpain in both human AF and a cell model for tachypacing-induced remodeling (11,12). 
Cal pains degrade cytoskeletal and contractile proteins ( 13 ), including cardiac troponins 
(13,14). We therefore hypothesized that AF causes calpain-induced troponin degradation, 
resulting in contractile and structural remodeling. Here, we exploit tachypaced HL-1 
cardiomyocytes to study the involvement of several proteases in the degradation of the 
myofibrillar proteins cTnT, cTnl, cTnC and actin. We also explore whether prevention of 
troponin degradation conserves contractile function. Additionally, we collected samples 
from patients with paroxysmal (PAF) and persistent (PeAF) AF to analyze alterations in 
myofibrillar protein expression. To directly test whether human cardiac troponins are 
targets for calpain-induced degradation, HL-1 cardiomyocytes were transfected with 
human cTnT and subjected to tachypacing in combination with various protease 
inhibitors. We obtained definitive evidence that calpain mediates cardiac troponin 
degradation and contractile dysfunction in in vitro and human tissue models for AF. 
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Materials and Methods 
HL-1 cardiomyocyte culture, tachypacing and major protease inhibition 
HL-I atrial cardiomyocytes, derived from adult mouse atria, were obtained from Dr. 
William Claycomb (Louisiana State University, New Orleans, USA) (15). The 
cardiomyocytes were maintained in Complete Claycomb Medium (JRH, UK) 
supplemented with l00µM norepinephrine (Sigma, The Netherlands) dissolved in 0.3mM 
L-ascorbic acid (Sigma), 4mM L-glutamine (Gibco, The Netherlands) and 10% FBS 
(Life Technologies, Gaithersburg, MD). They were cultured in flasks coated with 
12.Sµg/ml fibronectin (Sigma) and 0.02% gelatin (Sigma), in a 5 %  CO2 atmosphere at 
37°C. 
The spontaneous rate of HL-1 cardiomyocytes is ~0. 5 -lHz. To induce tachycardia, HL-1 
cardiomyocytes (2: 1 x 106 cells) were cultured on 4-well rectangular dishes (N uclon, The 
Netherlands), placed into C-DishlO0™-Culture Dishes (IonOptix Corporation, MA) and 
subjected to electrical field stimulation (3Hz) via the C-PacelO0™-Culture Pacer 
(IonOptix Corporation, The Netherlands) as described previously (12,16,17). We used 
lHz pacing as a control. 
Cal pain inhibitor PD 150606, pan-caspase inhibitor Z-VAD-FMK and proteasome 
inhibitor MG 132 were purchased from Calbiochem (The Netherlands). The pan-caspase 
inhibitor Z-VAD-FMK inhibits all caspases. HL-1 cardiomyocytes were treated with 
PD150606 (20µM), Z-VAD-FMK (50µM) or MG132 (I 0µM) two hours prior to 
tachypacing to achieve complete inhibition as determined by individual enzymatic assays. 
Construct, transfection and detection of fusion protein 
To study degradation of human cTnT, HL-1 cardiomyocytes were transiently transfected 
with the plasmid pcDNA5/FRT/TO (lnvitrogen, USA) driving the expression of full 
length human cTnT. The primers CGGGATCCACCATGTCTGACATAGAAGAG 
GTGGTGGAAG (forward) and AAGAATGCGGCCGCTTTCCAGCGCCCGGT 36 
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GACTTTAG (reverse) were used to amplify human cTnT with PCR from a human heart 
cDNA library (Stratagene, USA). To obtain V5-pcDNA5/FRT/TO vector, the 14 amino 
acid V5 epitope was cloned in the Notl and Apa! sites of pcDNA5/FRT/TO. In addition, 
cTnT was subsequently cloned in the BamHI and Notl sites of V5 -pcDNA5/FRT/TO 
vector to generate pV5-C-hucTnT. Lipofectamine (Life technologies, The Netherlands) 
was used to transiently transfect HL-1 cardiomyocytes according to manufacturer 
instructions. Expression of V5-C-hucTnT recombinant protein in cardiomyocytes was 
determined by Western blotting with mouse monoclonal Anti-VS -Antibody (R960-25 , 
lnvitrogen, USA). 
Measurement of calpain, caspase and proteasome activity 
Ca/pain 
Calpain enzymatic activity was determined with the use of a calpain activity assay kit 
(K240-100, Bio Vision, USA). Briefly, l x 106 cardiomyocytes were harvested and counted 
upon trypsinization. After cell suspension in 100µ1 Extraction Buffer, samples were 
incubated on ice for 20 minutes. The cell lysate was centrifuged for 1 minute ( 10,000g) 
and the supernatant was transferred to a fresh tube and put on ice. After 
protein-concentration determination (RC DC Protein Assay, Bio-Rad, The Netherlands), 
each sample was diluted into Extraction Buffer (5 0µg protein/85µ1), followed by the 
addition of 10µ1 of } Ox Reaction Buffer and 5µ1 Calpain Substrate to each assay-sample. 
Cal pain-activity was measured by fluorometry ( 400-nm excitation; 5 05 -nm emission) 
immediately after I-hour incubation of samples in the dark at 3 7 ·c . 
The calpain activity measurement in human tissue was performed as described previously 
(11 ). Suc-Leu-Leu-Val-Tyr-7-amino-4-methyl-coumarin (AMC, Sigma, The Netherlands) 
was used as substrate. Protein extract (25 µg) was added to 20µM AMC in 300µ1 
Tris-buffered saline. AMC release was measured by fluorometry (360-nm excitation; 
430-nm emission, Spectrometer LS50B, PerkinElmer, The Netherlands) after 30-min 
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incubation at room temperature. 
Caspase 
Caspase activity was measured using a caspase fluorometric assay kit (K1 05-1 00, 
Bio Vision, USA). Briefly, 1 x 1 06 cardiomyocytes were harvested and counted upon 
trypsinization. Cells were suspended in 50µ1 of chilled Cell Lysis Buffer and then were 
incubated on ice for 1 0  minutes. 50µ1 of 2xReaction Buffer and 5µ1 of l mM DEVD-AFC 
substrate (50µM final concentration) was added to each sample, followed by the 
incubation at 37°C for 2 hours. Finally, all samples were read in a fluorometer with 
400-nm excitation and 505-nm emission. 
Proteasome 
To determine involvement of the proteasome, HL-1 cardiomyocytes were transfected 
with a construct encoding Ubiquitin-R-GFP fusion protein (1 8). Ubiquitin-R-GFP 
converts stable GFP into a substrate vulnerable to ubiquitin-proteasome-dependent 
proteolysis. GFP turnover is then mediated by proteasome activity, and increased 
amounts of GFP indicate proteasome inhibition. To determine proteasome activity, 
cardiomyocytes were treated with or without the proteasome inhibitor MG 1 32 two hours 
before and during tachypacing. After 24 hours of tachypacing, flow cytometry was used 
to analyze the difference in the percentage of GFP positive cardiomyocytes between 
MG 1 32-treated and MG 1 32-non-treated cells. Cardiomyocytes paced at lHz with or 
without MG1 32 treatment served as controls. 
Contractility assessment by cell-shortening measurement and live imaging of Ca2+ 
transients 
Cell-shortening (CS) was measured as described previously (16, 1 9). Briefly, CS 
(maximum minus minimum cell-length) was measured with a video edge detector 
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(Crescent Electronics) coupled to a charge-coupled device camera. The contraction signal 
was digitized at 200 Hz (TL-1 AID Convert, Axon). Edge-detection cursors were 
positioned at both cardiomyocyte-ends to measure whole-cell shortening. CS was 
measured relative to diastolic cell-length based on the average of 10 consecutive beats. 
Ca2+ transients were imaged by Solamere-Nipkow-Confocal-Live-Cell-Imaging system 
(based on a Leica DM IRE2 Inverted microscope). 2µM of the Ca2+-sensitive Fluo-4-AM 
dye (Invitrogen) was loaded into HL-1 cardiomyocytes by 45-min incubation, followed 
by 3 times washing with PBS. Ca2+ loaded cardiomyocytes were excited by 488 nm and 
emitted at 5 00-5 50  nm and visually recorded with a 40x-objective. 
Patients 
Prior to surgery, one investigator assessed patient characteristics (Table 1) and classified 
arrhythmia history according to Gallagher and Camm (20). Persistent (n=l 7) and 
paroxysmal (n=l4) groups contained patientswith lone AF or AFwith underlying mitral 
valve disease (MVD). All patients were euthyroid and had normal left-ventricular 
function. Coumarin therapy was interrupted 3 days before surgery and class I and III 
anti-arrhythmic drugs were discontinued for at least 5 half-lives. Right and/or left atrial 
appendages (RAAs and LAAs respectively), were obtained from all patients, except for 
the control patients undergoing CABG from whom only the RAA was gathered prior to 
cardiopulmonary bypass (Table 1 ). After excision, atrial appendages were immediately 
snap-frozen in liquid nitrogen and stored at 85 °C. The investigation conforms to the 
principles of the Declaration of Helsinki. The Institutional Review Board approved the 
study and patients gave written informed consent. Samples from the same patients were 
used in a previous study (17). The amount of myolysis was quantified as described 
previously ( 17). An atrial myocyte was defined as myolytic when > 10% of the myocyte 
surface was free from myosin staining. Five randomly chosen fields or more of a total of 
250 - 500 myocytes were examined by three independent observers blinded for the 
experimental groups. Mean scores of the observers were used. 39 
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Table 1 Baseline demographic and clinical characteristics of patients with paroxysmal AF (PAF), 















Duration of AF  ( mediant range (months)) 
Duration SR before surgery (median .. range (days)) -
Duration of last episode AF (median. range (h)) 
1 t6 ( 0.1-56) 
10 (0.5-210) -
AF /day (median. range (�)) 
Underlying heart disease (n) and/or 
surgical procedure 
Coronary artery disease/CABG 
Lone AF/Maze 
MVD/MV repla,cementjrepair 
New York Heart Association for exercise tolerance 
Oass I 
Oass I I  
Oass I ll 
Echocardiography 
Left atrial diameter (parastemal) 
Left ventricular end-diastolic diameter (mm) 

































48± 4  
52±3 





Values are presented as mean value±SEM or number of patients. CABG: Coronary Artery Bypass 
Grafting; Maze: atrial arrhythmia surgery; MVD: mitral valve disease. *p<0.05. 
Protein-extraction and Western blot analysis 
Western blot analysis was performed as described previously (17,21 ). Equal amount of 
protein in SOS-PAGE sample buffer was sonicated before separation on 10% PAA-SOS 
gels. After transfer to nitrocellulose membranes (Stratagene, The Netherlands), 
membranes were incubated with primary antibodies against GAPOH (Affinity Reagents, 
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USA), cTnT (RDI-4T19-1A11), cTnl (RDI-TRK4T21-MF4), cTnC (RDl-4T27-1A2), 
cardiac actin (RDI-PRO61075), (all from RDI Division of Fitzgerald Industries Intl, 
USA). Horseradish peroxidase-conjugated anti-mouse (Santa-Cruz Biotechnology, The 
Netherlands) was used as secondary antibody. Signals were detected by the 
ECL-detection method (Amersham, The Netherlands) and quantified by densitometry. 
The amount of protein chosen was in the linear immunoreactive signal range and 
expressed relative to GAPDH. 
Statistical analysis 
Results are expressed as mean ± SEM. All Western-blot procedures were performed in at 
least duplicate series. ANOVA was used for multiple-group comparisons. Correlation of 
human data was determined using the Spearman correlation test, which is a 
non-parametric measure of correlation for small group numbers. All p values were 
two-sided. p< 0.05 was considered statistically significant. SPSS version 8.0 was used for 
statistical evaluation. 
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Results 
Tachypacing of HL-1 cardiomyocytes induces troponin degradation and activation 
of calpain and caspases 
To determine the putative consequences of tachypacing on myofibril degradation, we 
measured expression levels of troponins and actin in HL-1 cardiomyocytes. Exposure of 
HL-1 cardiomyocytes to tachypacing (3Hz) for up to 24 hours resulted in a gradual loss 
of cTnT, cTnl and cTnC, compared to l Hz pacing. Actin expression-levels were 
unaffected by tachypacing (Figure 1 A). As observed previously (11, 12), 24 hours of 
tachypacing of HL-1 cardiomyocytes resulted in significant induction of calpain activity, 
which was inhibited by pre-treatment with the specific cal pain inhibitor PD 150606 
(20µM, Figure l B). Since caspases and the ubiquitin-proteasome systems are involved in 
degradation of cardiac proteins and found to promote cardiac dysfunction in ventricular 
cardiomyocytes (22-24), the effect of tachypacing on caspase activity and on the 
proteasome was also studied. Tachypacing indeed induced caspases activation, which was 
inhibited by treating cardiomyocytes prior to and during tachypacing with the 
pan-caspase inhibitor Z-VAD-FMK (50µM, Figure IC). To assess the contribution of the 
proteasome to tachypacing-induced cardiac troponin degradation, cardiomyocytes were 
transiently transfected with Ubiquitin-R-GFP fusion reporter (18) with or without the 
proteasome inhibitor MG132 (IOµM). FACS analysis revealed that the percentage of GFP 
positive cardiomyocytes was unchanged after 24 hours of tachypacing (Figure ID), 
compared to IHz. Adding MG132 to both IHz and 3Hz paced cardiomyocytes caused 
accumulation of GFP, demonstrating that MG 132 effectively inhibited the proteasome 
activity (Figure ID). 
Calpain-mediated degradation of cardiac troponins 
To more conclusively determine whether calpain directly degrades cardiac troponins in 
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Figure 1 Tachypacing-induced degradation of cardiac troponins and activation of calpain and caspases. 
(A) Representative Western blots show that tachypacing (3Hz) decreases cTnT, cTnl and cTnC levels, 
compared to 1 Hz control cardiomyocytes. No alteration in the expression of actin was observed. (B) 
HL- 1 cardiomyocytes were paced at I Hz or 3Hz in the absence of PD1 50606 (-PD) or in the presence 
of PD I 50606 ( +PD). Cal pain activity was measured by monitoring fluorescence after specific 
cleavage of the test substrate. N=4 per group. *p<0.05 (3Hz-PD vs I Hz-PD). (C) HL- 1  
cardiomyocytes were 3Hz tachypaced o r  I Hz paced i n  the absence (-CAS) o r  i n  the presence (+CAS) 
of pan-caspase inhibitor Z-VAD-FMK. Caspase activity was measured by monitoring fluorescence 
after specific cleavage of the test substrate. N=4 per group. * =p<0.05 (3Hz-CAS vs 1 Hz-CAS ). (D) 
Proteasome activity was measured in 3Hz and I Hz paced HL- 1  cardiomyocytes pre-incubated either 
without (-MG) or with ( +MG) the proteasome inhibitor MG 1 32. Bar graphs represent the percentage 
of GFP positive HL- 1 cardiomyocytes. *=p<0.05 ( +MG vs -MG). 
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tachypaced HL-1 cardiomyocytes, cardiomyocytes were treated with the calpain inhibitor 
PD 150606 (20µM) prior to and during tachypacing. The mean amount of cardiac 
troponin expression is shown relative to GAPDH and plotted versus pacing duration. 
PD 150606 prevented tachypacing-induced degradation of cTnT, cTnI and cTnC (Figure 
2A-C). Incubation of HL-1 cardiomyocytes with the pan-caspase inhibitor Z-VAD-FMK 
(5 0µM) did not attenuate cTnT, cTnI or cTnC degradation (Figure 2D), suggesting no 
involvement of caspases in tachypacing-induced troponin degradation. In addition, 
degradation of cTnT, cTnI and cTnC was unaffected in tachypaced cardiomyocytes 
incubated with MG 132 ( 1  0µM, Figure 2E), indicating no involvement of the proteasome. 
In summary, the findings suggest that calpain, and not caspases or the proteasome, is the 
key component in tachypacing-induced degradation of cardiac troponins. 
Calpain-inhibition prevents tachypacing-induced contractile dysfunction 
To study if calpain-mediated cardiac troponin degradation is directly linked to contractile 
dysfunction, the effect of cal pain-inhibition on the degree of cell shortening (CS) of HL-1 
cardiomyocytes was assessed. While tachypacing markedly reduced CS of HL-1 
cardiomyocytes compared to lHz paced cardiomyocytes, the calpain inhibitior PD150606 
(20µM) completely prevented CS-depression (Figure 3). Pan-caspases and the 
proteasome inhibition did not attenuate tachypacing-induced contractile dysfunction in 
HL-1 cardiomyoctyes (data not shown). The effect of PD150606 on tachypacing-induced 
changes in Ca2+ transients was studied with l ive imaging. Tachypacing for 4 h induced 
loss of rhythmic fluorescence-signal, indicating reductions in Ca2+ transients, but 
PD150606 conserved Ca2+ transients (supplemental information movies 1-3). These 
observations demonstrate that calpain inhibition attenuates both tachypacing-induced 
cardiac troponin degradation and contractile dysfunction in HL-1 cardiomyocytes. 
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Figure 2 Calpain-mediated degradation of cardiac troponins. Top panels show representative 
immunoblots of cTnT (A), cTnI (B), and cTnC (C) in tachypaced (3Hz) HL- 1 cardiomyocytes, either 
in the absence (-PD) or the presence of (+PD) calpain inhibitor PD 1 50606. Bottom, the mean 
expression levels of cTnT, cTnI and cTnC are shown. N:;?!:4 for each data point. *p<0.05 (3Hz+PD vs 
3Hz-PD). Control groups were paced at !Hz, either in the absence (-PD) or the presence of (+PD) 
calpain inhibitor PD 1 50606. (D) Representative immunoblots of cTnT, cTnl and cTnC in tachypaced 
(3Hz) HL-1 cardiomyocytes, either in the absence of (-CAS) or the presence of pan-caspase inhibitor 
(+CAS). (E) Representative immunoblots of cTnT, cTnl and cTnC in tachypaced (3Hz) HL- 1 
cardiomyocytes, either in the absence of (-MG) or the presence of MG 1 32 ( +MG). 
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Figure 3 Calpain inhibition prevents tachypacing-induced contracti le dysfunction. (A) Original 
recordings of cell shortening (CS) in one cell each from groups indicated. (B) CS was measured in 
tachypaced (3Hz) and lHz paced HL- 1 cardiomyocytes either in the absence (-PD) or the presence of 
( +PD) cal pain inhibitor PD 1 50606. Tachypacing significantly resulted in the reduction of CS, while 
the cal pain inhibitor PD 1 50606 prevents CS reduction. N=8 to 12 cel ls/data point. * * p<O.O I vs O hour 
Degradation of cardiac troponins in patients with atrial fibrillation 
To extend the findings on calpain-mediated degradation of cardiac troponins in the cell 
model in relation to high levels of myolysis in PeAF (11), cardiac troponin levels were 
determined in atrial tissue from PeAF, PAF and sinus rhythm (SR) control patients. 
Results are shown in Figure 4, with patients l acking known atrial disease in fil led circles 
and mitral valve disease patients in open symbols. PeAF patients showed a significant 
reduction in cTnT levels (3 8 k.Da), compared to SR patients (Figure 4A). Moreover, after 
longer exposure of the blot, a 25 k.Da cleavage product was observed in PeAF, but not in 
SR and PAF (Figure 4B). The expression levels of cTnl (Figure 4C) and cTnC (Figure 4E) 
were significantly reduced in patients with PeAF compared to patients with either SR or 
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Figure 4 Patients with persistent AF (PeAF) show degradation of troponins. Representative 
immunoblots showing the decreased expression of full length cTnT (A), cTnl (B), cTnC (C) in atrial 
tissue of patients with persistent AF (PeAF) compared to paroxysmal AF (PAF) and controls in sinus 
rhythm (SR). In overexposed blots, a significant increase in the degradation product for cTnT (25kDa) 
(D) and cTnl ( 1 5kDa) (E) is observed in PeAF compared with PAF and SR. All groups show similar 
expression of actin (F). (e)  represents Ione AF patients or SR patients undergoing CABG, (□) 
represents patients with mitral valve disease. 
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Figure 5 Myolysis and calpain-activity correlate with the amount of troponin degradation products in 
AF patients. (A) There is a significant correlation between the degree of myolysis and the amount of 
human 25k.Da cTnT degradation-product (R=0.38, p=0.03). (B) The significant correlation between 
the degree of myolysis and the amount of human 1 5k.Da cTnl degradation-product (R=0.40, p=0.02). 
(C) Significant induction of calpain was found both in PAF and PeAF patients, compared to patients 
with SR. (D) The significant correlation between calpain activity and the amount of human 25k.Da 
cTnT degradation-product (R=0.5 1 ,  p<0.000 1 ). (E) The significant correlation between calpain 
activity and the amount of human l 5kDa cTnl degradation-product (R=0.5 1 ,  p<0.000 I ). ( • )  
represents lone persistent AF patients, (□ ) represents patients with lone paroxysmal AF, (o) represents 
SR patients undergoing CABG, (□)  represents SR patients with mitral valve disease, ( D )  represents 
paroxysmal AF patients with mitral valve disease, (■)  represents persistent AF patients with mitral 
valve disease. 
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P AF. For cTnI, a 15 kDa degradation fragment was detected in PeAF patients (Figure 
4D). For cTnC, no degradation fragments were detected. Consistent with our in vitro data, 
no alterations in the expression levels of actin were observed (Figure 4F). 
Previously, we reported ultrastructural changes in atrial tissue of a part of this patient 
population ( 11 ). In patients with lone persistent AF, a substantial fraction of cells was 
myolytic (30.0±14.5 %), whereas in tissue of patients with lone paroxysmal AF myolysis 
was low (6. 9±6.1 %) and similar to control patients (5 . 5±3.6%). In the lone AF patients in 
the present study, we found a significant correlation between the extent of myolysis and 
the amounts of 25 kDa cTnT and 15 kDa cTnI degradation products (Figure S A, B, 
respectively). This observation indicates that myolysis is associated with troponin 
degradation product accumulation. 
To study whether a relation exists between calpain activity and human cTnT and cTnl 
degradation, calpain activity was measured in tissue samples from AF patients and SR 
controls. A significant induction of cal pain activity was observed in P AF (2-fold increase, 
p<0.001) and PeAF (3. 5-fold increase, p<0.0001) vs SR controls (Figure SC). Significant 
correlations were found between calpain activity and cTnT 25 kDa and cTnI 15 kDa 
degradation products (Figure SD, E), i.e. high calpain activity was associated with large 
amounts of troponin degradation products. Together, the human findings are in 
accordance with our observations in tachypaced HL-1 cardiomyocytes and suggest a 
causative relationship between AF-induced calpain activation and troponin degradation. 
Tachypacing-induced degradation of human cTnT in HL-1 cardiomyocytes 
To establish whether the 25 kDa human cTnT fragment results from cleavage by calpains, 
HL-1 cardiomyocytes were transfected with a tagged human cTnT (pV5-C-hucTnT) and 
subjected to tachypacing. With the VS antibody, the 25 kDa degradation product of 
V5 -C-hucTnT fusion protein was detected in tachypaced cardiomyocytes (Figure 6), 
while pre-treatment with the cal pain inhibitor PD 150606 (20 µ M) completely abolished 
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its appearance (Figure 6). No attenuation of the tachypacing-induced 25 kDa 
V5-C-hucTnT degradation product was observed in cardiomyocytes pretreated with 
pan-caspases or proteasome inhibitor (Figure 6). These findings confirm that calpain 
activation mediates the cleavage of human cTnT into a 25 kDa fragment, as observed in 
patients with PeAF. 
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0 18 20 22 24 0 18 20 22 24 
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-e- 1 Hz-P D 
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Figure 6 Tachypacing induces degradation of human cTnT in HL- 1 cardiomyocytes. V5-C-hucTnT 
transfected HL- 1 cardiomyocytes were tachypaced (3Hz) or paced at l Hz in the absence of (-PD) or in 
the presence (+PD) of the calpain inhibitor PD 1 50606, pan-caspase inhibitor Z-VAD-FMK (+CAS) 
and the proteasome inhibitor MG 132 (+MG). Top shows typical Western blot demonstrating the 
appearance of a cTnT degradation product of 25kDa by tachypacing, which was abolished by 
PD l 50606. Bottom, quantification of V5-C-hucTnT cleavage products. ***p<0.00 1 (3Hz+PD vs 
3Hz-PD). 
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Discussion 
In this study, we show that in vitro tachypacing of HL-1 atrial cardiomyocytes results in 
the gradual degradation of cTnT, cTnI and cTnC, which is exlusively mediated by cal pain 
activation. In addition, contractile dysfunction of tachypaced cardiomyocytes was 
prevented by calpain inhibition. In atrial tissue from patients with PeAF, a significant 
degradation of cTnT, cTnl and cTnC was observed, which correlated with the degree of 
myolysis and calpain activity. Finally, a specific 25kDa degradation product of cTnT 
observed in PeAF was found to originate from calpain-mediated cleavage. Previously we 
showed that tachypacing of HL-1 atrial cardiomyocytes induces the prime features of 
atrial remodeling, including contractile dysfunction, ion-channel and structural 
remodeling (12,16, 17). Our results suggest that calpain activation represents a key factor 
underlying myofibrillar protein degradation, myolysis and contractile dysfunction. Since 
myolysis and contractile dysfunction contribute to the AF substrate (1,2), calpain 
activation may relate to the self-perpetuating nature of AF. 
Tachypacing-induced troponin degradation: a central role for calpain 
It has been recognized that calcium overload via the L-type calcium channel plays a 
major role in cardiomyocyte remodeling during AF (19,25 ). Calcium overload can 
activate calpain (13) and calpain activation was consistently induced in our 
cardiomyocyte model for tachypacing-induced remodeling (11,12). In atrial tissue from 
AF patients, calpain-activity was also significantly elevated (11) and in the present study 
correlated with the amount of troponin degradation product. Additionally, the resulting 
calcium overload inactivates L-type calcium channel and affects the calcium-handling 
apparatus, which lead to secondary abnormalities in calcium-release that result in reduced 
calcium transient amplitude and consequently decreased CS. Therefore, calcium 
represents a mediator of tachycardia-induced atrial contractile dysfunction (19). As both 
tachypacing-induced troponin degradation and contractile dysfunction are attenuated by 
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the specific cal pain inhibitor PD 150606, our current data point to a functional relation 
between the two events, i.e. activation of calpains results in degradation of troponins, 
which consequently causes contractile dysfunction. 
We also investigated two other major protease systems, caspases and the proteasome. 
While caspases are activated as a result of tachypacing, any role in contractile-protein 
degradation seems minimal, since effective pan-caspase inhibition did not attenuate 
cardiac troponin degradation and contractile dysfunction. Although caspases degrade 
cTnT leading to contractile dysfunction in ventricular cardiomyocytes (22), other studies 
revealed that calpain, in addition to direct degradation of proteins (13,14), can induce 
caspase-12 activation, which might result in protein-degradation (26,27). These findings 
and our observations suggest that upon atrial-tachypacing, calpain specially degrades 
cardiac troponins, further supporting our hypothesis that calpain and not caspase plays a 
key role in mediating tachypacing-induced troponin degradation. 
The ubiquitin-proteasome system plays an important role in degradation of proteins (24) 
and promotes cardiac dysfunction in pressure-overloaded hearts (23 ). In the present study, 
no role for the proteasome was found in atrial tachypacing-induced degradation of 
cardiac troponins. This finding agrees with a previous study in which we observed no 
effect of the proteasome on tachypacing-induced ion-channel remodeling (11). 
Collectively, our data indicate that tachypacing of HL-1 atrial cardiomyocytes results in 
the degradation of troponins, which is mediated by activation of cal pain. Although these 
systems have been implicated previously in AF (8, 11 ), the present study is the first to 
provide definitive evidence for the role of cal pain, and the lack of a role for caspases and 
proteasome, in troponin degradation and contractile dysfunction in both in vitro 
tachypaced HL-1 atrial cardiomyocytes and human-tissue models for AF. In human AF, 
we observed degradation of cTnT, cTnI and cTnC only in PeAF patients, compared to 
PAF and SR. A significant correlation was observed between calpain activity and the 
amount of degradation product of cTnT and cTnl and a specific cleavage product was 
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Ca/pain mediates cardiac troponin degradation found only in PeAF. A simi lar cleavage product was observed after tachypacing of human cTnT-transfected HL- 1 cardiomyocytes. The appearance of this 25kDa fragment directly results from calpain activation, as its presence was prevented by inhibition of calpains, but not by inhibition of other proteases. Together, the findings suggest that in both human AF and tachypaced HL- 1 cardiomyocytes, calpain mediates the degradation of cardiac troponin. The 25kDa fragment of cTnT was found only in PeAF patients and tachypaced HL-1 cardiomyocytes transfected with human cTnT, but not in untransfected cardiomyocytes. Therefore, the detection of the 25 kDa cleavage product might be interpreted as a possible marker for glyocogen positive and hibernation like cardiomyocytes. The absence of the 25kDa fragment in native HL- 1 cells is probably due to differences in N-terminal amino-acid sequence between human and mouse cTnT (28) resulting in the absence of a calpain cleavage site in mouse, since the N-terminal sequence is highly heterogenous. 
Implications of calpain activation for AF It is commonly recognized that AF induces changes at the structural level, predominantly myolysis, which contributes to contractile dysfunction and the progression of AF ( 4,5,29,30). Our in vitro findings combined with human AF data indicate that cal pain activation and troponin degradation are closely associated with persistent AF. This observation suggests that Ca2+ -overload and subsequent calpain-activation play a role in the self-perpetuation of AF. As cardiac troponin is an important protein-complex of the thin filament to regulate contraction (22,3 1 -33), calpain-mediated troponin degradation wil l  affect contractile function and might therefore be involved in the self-perpetuation of AF. This observation is in l ine with calpain-induced troponin degradation and the progression of heart failure (34). Furthermore, atrial hypocontracti l ity plays an important role in the thromboembolic complications associated with AF (35). Thus, calpain may be a therapeutic target in cardiac disease. 
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Since cTnT and cTnI are structurally different from the corresponding forms in skeletal 
muscle, measurement of serum cTnT and cTnI in patients with heart diseases is 
recognized to be clinically important in the prediction of severity, prognosis and 
treatment selection (36). However, so far cardiac troponin is not used as a biomarker in 
patients with AF. Our study suggests the possibility that the serum concentrations of 
troponin degradation-products may be applicable as a biomarker in AF patients. 
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Abstract 
Atrial fibrillation (AF) causes myocyte stress by inducing structural changes, 
predominantly myolysis, which is related to the progression of AF. As heat shock 
proteins (Hsp) protect against cellular stress, their efficacy in preventing myolysis was 
investigated in a tachy-paced cell model for AF and in patients with AF. HL-1 atrial 
myocytes were subjected to tachy-pacing, which induced myolysis. Hsp overexpression 
was accomplished by a mild heat shock or by the drug geranylgeranylacetone (GGA). 
Hsp-gene-transfection studies were carried out to investigate roles of individual Hsp. In 
left and/or right atrial appendages from patients with paroxysmal (n=l4), persistent (n=l 7) 
AF and controls (n=l3) in sinus rhythm (SR), Hsp levels (Westerns) and localization 
(confocal microscopy) were determined. Heat shock and GGA administered prior to 
tachy-pacing resulted in almost complete protection against tachy-pacing-induced 
myolysis. Overexpression of Hsp27, but not of Hsp70, also provided complete protection 
against pacing-induced myolysis. In patients with paroxysmal AF, Hsp27 expression was 
significantly increased compared to SR and persistent AF. No changes in Hsp40, Hsc70, 
Hsp70 and Hsp90 expression levels were observed. Hsp27 levels correlated inversely 
with the duration of paroxysmal and persistent AF and the extent of myolysis. 
Furthermore, Hsp27 was localized on myofibrils in tachypaced HL-1 myocytes and in 
human cardiomyocytes. These data demonstrate that upregulation of Hsp, especially 
Hsp27, protects tachy-paced atrial myocytes from myolysis. Therefore, the observed 
elevated Hsp27 expression in patients with paroxysmal AF might serve to protect 
myocytes from myolysis and limit the progression to persistent AF. Pharmacological 
induction ofHsp, with drugs such as GGA, may represent a novel therapeutic approach in 
AF. 
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Introduction 
Atrial fibrillation (AF) is the most common cardiac arrhythmia which has the tendency to 
become more persistent over time (1). Research exploring the underlying mechanisms of 
the self-perpetuation of AF has demonstrated that AF leads to shortening of atrial 
effective refractory periods (AERP), heterogeneity of the electrical activation pattern and 
loss of contractile function (2). When the arrhythmia continues, AF induces changes at 
the structural level, predominantly myolysis, which are associated with the progression of 
AF (3-8). 
Myolysis is characterized by disruption of the myofibril structure (3,9,10) and observed 
after various forms of cell stress such as ischemic stress (11) and hypoxia (12). 
Furthermore, it is well known that some Hsps, especially Hsp70 and Hsp27, protect 
against the degradation of myofibrils. Hsp70 is able to bind and protect microtubule 
network and therefore limit myofibril disruption after ischemic stress in myocardium (13). 
Also, in cells overexpressing Hsp27, F-actin and myofibril structure are protected against 
heat- or ischemia-induced disruption (14-18) and recovery after disruption is accelerated 
(19). Because of these protective roles of Hsp, we studied whether upregulation of Hsps 
prior to and during pacing can protect against tachypacing-induced myolysis in an 
established cell model for AF (20,21 ). In this model, induction of Hsp synthesis was 
performed by a mild heat shock or by the drug geranylgeranylacetone (GGA). GGA, 
clinically employed as an antiulcer agent, is a non-toxic acyclic isoprenoid compound 
with a retinoid skeleton that induces Hsp synthesis in various tissues including gastric 
mucosa, intestine, liver, myocardium, retina and central nervous system under stress 
(22-24). In the present study, we found that Hsp upregulation protects against 
pacing-induced myolysis. Notably, the sole overexpression of one member of Hsp, Hsp27, 
was sufficient for this protection. 
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Materials and Methods 
HL-1 cell culture conditions, transfections and constructs 
The HL-1 atrial myocytes, developed from adult mouse atria (25), were obtained from Dr. 
William Claycomb (Louisiana State University, New Orleans, LA, USA) and cultured as 
described before (20). 
Lipofectamine (Life technologies, The Netherlands) was used for transient transfections 
according to instructions of the manufacturer. pHsp70-YFP encodes a functional human 
Hsp70 fused to YFP under control of a CMV promoter. pHsp27 encodes human Hsp27 
under control of CMV promoter (Clontech, The Netherlands). Hsp27 transfected 
myocytes were detected by immunofluorescent staining with the human specific Hsp27 
antibody (SP A800, StressGen Biotechnologies, Victoria, Canada) and myocytes 
overexpressing human Hsp70-YFP were distinguished from non-transfected myocytes on 
the basis of the YFP signal. 
Pacing and induction of Hsp expression 
HL-1 myocytes (� Ix 106 myocytes) were cultured on coverslips and subjected to a 
I O-fold rate increase (tachypacing) by the use of a C-PacelO0™-culture pacer and 
CDishl O0™-culture dishes (IonOptix Corporation, The Netherlands). Myocytes were 
stimulated at 5 Hz with square pulses of 5 ms duration and a pulse voltage set to 45 V. 
Evidence of capture was examined by microscopic examination of cell shortening at the 
beginning and before termination (after 24 h pacing) of stimulation. Capture efficiency at 
these time points was >90% for myocytes attached on gelatin/fibronectin-coated 
coverslips. Furthermore, the role of non-specific factors, such as electrolysis at the 
electrodes, was excluded by placing control myocytes outside the electrical field by the 
use of a specially developed pacing system. In this system, coverslip-cultured myocytes 
can be placed either within the electric field or outside the electric field. Control 
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myocytes placed outside the electric field showed no signs of myocyte remodeling, 
whereas myocytes placed in the electric field revealed myocyte remodeling (20). 
Elevation of Hsp expression in cultured myocytes was accomplished in 3 ways: (I) by 
subjection to a modest heat shock at 43 °C for 30 min followed by overnight incubation 
at 37 °C, (II) by incubation with 0.1 µ M geranylgeranylacetone (GGA, gift from Eisai 
Co. Japan) 2 h prior to and during pacing and (III) by transfection of pHsp70-YFP or 
pHsp27 24 h prior to pacing. The concentration-dependent increase in Hsp expression by 
GGA was tested at 0.1, 1 and 10 µ M. Since 90% of the maximum effect on induction of 
Hsp expression was already reached at 0.1 µ M GGA, all experiments were performed at 
this concentration. 
Patients 
Prior to surgery, one investigator assessed the clinical characteristics of the patients 
(Table 1 ). The patient's arrhythmia history was classified according to Gallagher (26). 
The persistent (n=l 7) and paroxysmal (n=l4) group contained patients with lone AF or 
AF with underlying mitral valve disease (MVD). All patients were euthyroid and had 
normal left ventricular function. Coumarin therapy was interrupted 3 days before surgery 
and class I and III antiarrhythmic drugs were discontinued for at least 5 half times. Right 
and/or left atrial appendages (RAAs and LAAs, respectively) were obtained from all 
patients, except for the control patients undergoing CABG from whom only the RAA was 
gathered prior to cardiopulmonary bypass (Table I ). After excision, the atrial appendages 
were immediately snap-frozen in liquid nitrogen and stored at -85 °C. The Institutional 
Review Board approved the study and patients gave written informed consent. 63 
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Table 1 Baseline characteristics of patients with paroxysmal AF (PAF), persistent AF (PeAF) and control patients in  sinus rhythm SR PAF .PeAF 
11 13 14 1 7  RAA {n) 1 1  12 1 6  LAA (n) 5 12 16  
Age 61;!;4 50;!;3 53;1;3 Du.ration of AF I 1 .6 (0,1-56) (m<:dian. range (months)) Duration SR before surgery 10 {0..5-210) -(median, rMgc (day:$)) Dur,1tion oflast episode AF 12 (0.2-24) (median. range {h)) AFlday(mroimtJ range (%)) 2 (02-70) Underlying heart disease (1,) and/1)1.lfgical procedure 
CoroQl31)' artery diseasc/CABG 8* 0 0 Lone AF/Maze 0 8 9 TVIVD/IvfV replacement/repair 5 6 8 New York Heart Association for 
c�crtisc tolerance Class I 10* 6 5 Class IT 3 5 8 Class HI 0 3 4 Sy$tolic blood pressure 147±4 14 l ;J;9 135::1;7 Diasto lie blood pre.s.,'Ure 84±2 81 ;1;;3 86;1;2 Echo<:ardiograpby Left atrial diameter (p;ua.-;tcrnal) 42;1,;3 42±4  48:l:;4 Left ventricular end-diastolic 50 ±4 52± 3  52±3 diameter (mm) Left vcntricufar end-systolic 34 -tA 38±3 34::l:5 <,liameter {rnm) Medication (11) Ace-inhibitors 4 5 7 Digitalis 0 1 7* Vcrapamil 6 3 4 Beta-blocker 4 3 4 Hsp/GAPDH protein ratio Hsp27 0,7±:0.05 l .H0.07* 0.8±0.08 H�-p40 l.2±0.2 1 .4;!-03 1 .4±0.2 Hsc70 0. 7±0.2 0.8¼0.2 0 .7:±;0.l Hsp70 0.6 :1;0.2 J .0±0.3 0.7;1;03 lh-p9() L2±0.3 U ±0.6 1 3±0.4 Values are presented as mean value±SEM or number of patients. CABG: Coronary Artery Bypass Grafting; Maze: atrial arrhythmia surgery; MVD: mitral valve disease. *p<0.05. 
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Protein extraction and Western blot analysis 
For Western blot analysis, frozen RAAs and LAAs were used for protein isolation as 
described previously (27). For the isolation of proteins from HL-1 myocytes, the cells 
were Iysed by the addition of SDS-PAGE sample buffer followed by sonication before 
separation on 10% PAA-SDS gels (1. 105 cells/slot). After transfer to nitrocellulose 
membranes (Stratagene, The Netherlands), membranes were incubated with primary 
antibodies against GAPDH (Affinity Reagents, USA), rodent Hsp25 (SPA801), human 
Hsp27 (SPA800), Hsp40 (SPA400), Hsc70 (SPA8 l 5 ), Hsp70 (SPA8 l 0) or Hsp90 
(SPA835) (all StressGen Biotechnologies, Victoria, Canada). Horseradish 
peroxidase-conjugated anti-mouse, anti-rat or anti-rabbit IgG (Santa-Cruz Biotechnology, 
The Netherlands) was used as secondary antibody. Signals were detected by the 
ECL-detection method (Amersham, The Netherlands) and quantified by densitometry. 
The amount of protein chosen was in the linear immunoreactive signal range and 
expressed relative to GAPDH. 
lmmunofluorescent staining, quantification and confocal analysis 
After subjecting HL-1 myocytes to tachy-pacing, the cells were fixed for 10 min in I 00% 
methanol (-20 °C), dried and blocked in 5%  BSA (20 min room temperature). Antibodies 
against myosin heavy chain (MF-20, Developmental Studies Hybridoma Bank, Baltimore, 
MD, USA) or Hsp27 (StressGen Biotechnologies, Vicotria, Canada) were used as 
primary antibody. Fluorescein labeled isothiocyanate (FITC) anti-mouse and anti-rabbit 
(Jackson ImmunoResearch, The Netherlands) or N, N' (dipropyl) -tetramethyl 
-indocarbocyanine Cy3 anti-mouse (Amersham, The Netherlands) was used as secondary 
antibody. Nuclei were visualized by 4', 6-diamidino-2-phenylindole (DAPI) staining. 
Images of FITC, YFP or CY3 and DAPI fluorescence were obtained by using a Leica 
confocal laser-scanning microscope (Leica TCS SP2). 
For the quantification of the amount of myolysis, 5 fields or more were examined with a 
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total amount of 25 0 - 500 myocytes, and myosin disruption ( characteristic for myolysis 
(3)) was scored by three independent observers blinded for the experimental groups. An 
atrial myocyte was defined as myolytic when > 10% of the myocyte surface was free from 
myosin staining (3,28). Mean scores of the observers were used. 
Definitions 
Persistent AF 
Continuous presence of AF until the moment of cardiac surgery, i .e. at least two 
consecutive electrocardiograms of AF more than 1 week apart, without intercurrent sinus 
rhythm. Persistent AF has a non-spontaneously converting character. Previously, this type 
of AF was classified as chronic AF (29). 
Paroxysmal AF 
AF typically occurring in episodes with a duration shorter than 24 h (but longer lasting 
paroxysms are not unusual) with intermittent sinus rhythm. Paroxysmal AF either 
converts spontaneously or is terminated by intravenously administered antiarrhythmic 
drug. It is non-controlled whether paroxysmal AF is present at the moment of cardiac 
surgery (29). 
Statistical analysis 
Results are expressed as mean±SEM. All Western blot procedures were performed in 
duplicate series and morphological quantifications were performed in duplo series of at 
least n=6 wells per series. Mean values were used for statistical analysis. ANOV A was 
used for multiple group comparisons. Correlation was determined using the Spearman 
correlation test. All p values were two-sided, a p value of <0.05 was considered 
statistically significant. SPSS version 8.0 was used for all statistical evaluations. 
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Results 
Hsp protect HL-1 myocytes from myolysis 
To address whether Hsp can protect from myolysis induced by AF, we applied a 
tachy-paced cell model for AF which reveals characteristic features of AF (20), including 
the induction of myolysis (Fig. lB). To test whether increased Hsp expression is capable 
of protecting against tachy-pacinginduced myolysis, myocytes were pretreated with a 
mild non lethal heat shock (30 min at 43 °C) and tachy-paced from 16 h afterwards. This 
mild heat shock induced all major heat shock proteins, including Hsp27 (in rodents often 
referred to as Hsp25) and Hsp70 prior to and during pacing (Fig. IA). Heat-treated 
myocytes showed less pacing-induced myolysis than non-pretreated paced myocytes 
(Figs. lB, C). 
To test whether pharmacological induction of Hsp with the non-toxic drug GGA was able 
to protect from myolysis, GGA was applied 2 h prior to and during pacing. Pacing in 
combination with GGA treatment led to significant elevations in Hsp27 and Hsp70 
expression (Fig. IA), which coincided with a significant reduction in pacing-induced 
myolysis compared to normal paced myocytes (Figs. lB, D). 
Hsp27 overexpression is sufficient for protection from tachypacing-induced myolysis 
To conclusively establish whether or not Hsp upregulation directly protects from 
pacing-induced myolysis and to study which Hsp conveys this protection, HL-1 atrial 
myocytes were transiently transfected with plasmids either encoding human Hsp27 or 
human Hsp70. In myocytes transiently overexpressing human Hsp27, as detected by 
immunofluorescent staining with a human specific Hsp27 antibody (Fig. 2A, left panel), a 
significant reduction of pacing-induced myolysis compared to normal paced myocytes 
was found (Fig. 2B). The protection mediated by overexpression of Hsp27 alone was as 
efficient as seen after heat-shock or GGA treatment. Furthermore, partial colocalization 
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Figure 1 The effect of induction of Hsp levels on pacing-induced myolysis. (A) Western blots show 
that a heat shock (HS) or GGA treatment (GGA) induces the expression of endogenous Hsp27 and 
Hsp70 in time, but do not change GAPDH levels, compared to non-treated myocytes ( control). 
Increased levels are maintained during pacing. (B) Immunofluorescent staining of myosin (green) in 
non-paced myocytes (Con), heat-shocked control myocytes (Con HS) and GOA-treated control 
myocytes (Con GGA) compared to 1 6  h paced myocytes (Paced), paced HS myocytes and paced 
GOA-treated myocytes. Paced myocytes reveal disruption of myosin (myolysis), whereas myosin 
staining remains diffusely distributed in the cytoplasm of paced myocytes treated with either HS or 
GGA. (C) Quantification of percentage myocytes showing myolysis as a function of time of pacing in 
control and heat-shocked myocytes (non-paced myocytes 0, non-paced HS myocytes □, paced 
myocytese ,  paced HS myocytes ). (D) Quantification of percentage myolysis in GOA-treated 
myocytes (non-paced control myocytesO,  non-paced GGA myocytes □, paced myocytes • and 
paced GGA myocytes ). *=significant increase compared to non-paced myocytes (p<0.01); 
#=significant reduction compared to paced myocytes (p:::c;0.05). 
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and relevant target proteins. In contrast, myocytes transiently overexpressing human 
Hsp70-YFP, distinguished from non-transfected myocytes on the basis of the YFP signal 
(Fig. 2A, right panel), were not protected against pacing-induced myolysis (Fig. 2B). 
Together, the results demonstrate that a general induction of Hsp expression protects 
against pacing-induced myolysis and that the sole overexpression of Hsp27, but not 







Figure 2 The effect of human Hsp27 or Hsp70 expression on pacing-induced myolysis. (A) 
Immunofluorescent staining of human Hsp27 (green), Hsp70-YFP (green) positive myocytes, myosin 
(red) and nuclei (DAPI, blue) in 16 h paced myocytes. Co-localization of Hsp27 with myosin was 
observed (yellow). (B) Quantification of the percentage myolysis in Hsp27 expressing myocytes 
(paced Hsp27 , non-paced Hsp27 0), Hsp70 expressing myocytes (paced Hsp70 , non-paced 
Hsp70 ) and in untransfected control myocytes (paced myocytes • ,  non-paced control myocytes 
0 ). *=significant increase compared to non-paced control myocytes (p<0.0 1) ;  #=significant 
reduction compared to paced control myocytes (p::::;0.05). 
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Hsp expression correlates with duration of persistent AF and structural changes 
In extension to the findings in the tachy-paced cell model for AF, Hsp levels in atrial 
tissue from patients with AF were determined. Protein isolated from atrial appendages 
was used for immunological detection of Hsp27, Hsp40, Hsc70, Hsp70 and Hsp90. 
Changes in protein expression were studied in relation to protein levels of GAPDH, 
which did not differ between the groups ( data not shown). The protein expression of 
Hsp27 (Fig. 3 A) was significantly increased in RAAs and LAAs from patients with 
paroxysmal AF compared to samples from control patients (p<0.0001) and patients with 
persistent AF (p<0.0001 ). A trend for increased Hsp70 expression (p=0.05) was observed 
in patients with paroxysmal AF compared to control patients (Fig. 3B, Table 1 ). No 
significant differences in the expression levels of Hsp40, Hsc70 and Hsp90 (Fig. 3B, 
Table 1) were found between the groups and no significant differences between RAA and 
LAA within the groups were observed. Also, no significant differences in Hsp27 levels 
were observed between tissue from lone AF patients and AF patients with underlying 
valve disease. Since increased Hsp27 levels were only found in tissue from paroxysmal 
AF patients, this may reflect that Hsps are merely activated in acute stress conditions and 
become exhausted during prolonged stress (30,31 ). To test this, a correlation was made 
between the duration of persistent AF and Hsp27 levels. A significant inverse correlation 
was observed between the duration of persistent AF and Hsp27 expression (Fig. 3C). 
Patients with a shorter duration of AF revealed higher levels of Hsp27 expression. Also a 
significant inverse correlation was observed between the duration of the last episode of 
AF and the Hsp27 levels in patients with paroxysmal AF (Fig. 3D). Paroxysmal AF 
patients with short period of AF display higher levels of Hsp27 expression. No significant 
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Figure 3 Protein expression levels ofHsp27 (A) in atrial tissue of patients with paroxysmal AF (PAF), 
persistent AF (PeAF) and controls in sinus rhythm (SR). Protein expression levels were determined by 
Western blotting and expressed as ratios over GAPDH. Inserts show part of typical Western blots. 
Patients with PAF reveal significant increase in Hsp27 protein ratios compared to controls in sinus 
rhythm (SR). (B) Part of typical Western blots showing Hsp90, Hsp70, Hsc70 and Hsp40 expression 
levels in SR, paroxysmal AF or persistent AF patients. (C) Correlation between Hsp27/GAPDH 
protein ratio and duration of persistent AF (PeAF). (D) Correlation between Hsp27 /GAPDH protein 
ratio and duration of last episode of paroxysmal AF (P AF). ( •) Represents lone AF patients or SR 
patients undergoing CABG, C@) patients with AF or SR and mitral valve disease. 
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Previously, we reported on (ultra)structural changes in atrial tissue of a part of this patient 
population (28). In brief, in 7 patients with lone persistent AF, a substantial fraction of 
cells was myolytic (30.0±14. 5%), whereas the percentage of myocytes with myolysis in 
tissue of 6 patients with lone paroxysmal AF was low ( 6.9±6. 1 % ) and similar to that in 
control patients (5 . 5±3 .6%). In this sub-group of AF patients, we found an inverse 
correlation between the amount of myolysis and Hsp27 expression (Fig. 4A), i.e. high 
Hsp27 levels in tissue of patients were associated with low amounts of myolysis. 
Furthermore, confocal microscopy revealed that, like in the tachy-paced cell model for 
AF, Hsp27 was preferably localized on myofibrils in cardiomyocytes (both of SR and AF 
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Figure 4 An inverse correlation was found between the extent of myolysis and protein expression levels of Hsp27 (A) in RAAs of patients with paroxysmal AF (0) and persistent AF (• ). (B) Typical example of an immunofluorescent staining of Hsp27 (green), Hsp70 (red) and nuclei (DAPI, blue) in atrial tissue of a patient in sinus rhythm (SR) and with paroxysmal AF (P AF). Hsp27 is localized on the myofibrils in cardiomyocytes (arrowhead), whereas Hsp70 is located in the cytosol and extracellular matrix. 
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Discussion 
The present study identifies a protective role for Hsp in AF. Using the HL-1 cell model 
for AF (20), we provided evidence that upregulation of Hsp by a mild heat shock and 
pharmacologically by the drug GGA, attenuates myolysis. Furthermore, transfection 
experiments directly demonstrated that elevated expression of Hsp27 alone was sufficient 
for this protection. The results were extended to human AF, where a highly significant 
increase of Hsp27 expression was observed only in atrial appendages of patients with 
paroxysmal AF. In addition, the expression levels of Hsp27 correlated inversely with the 
duration of the arrhythmia and with the amount of myolysis in paroxysmal and persistent 
AF. Finally, like in the tachypaced cell model for AF, Hsp27 was found to be localized at 
the myofilaments in human atrial myocytes. Our data imply that Hsp upregulation 
protects against tachypacing-induced myolysis. 
Mechanism of Hsp protection 
Several mechanisms may explain how Hsp27 protects myocytes from tachypacing 
-induced myolysis. Pacing directly, or via increases of intracellular free calcium and 
calpain activation (20,28,32), results in disruption of myofibril structures (3). A first 
possibility is that Hsp27 binds to the myofibril structure, as suggestive from the 
( co )localization of Hsp27 with myosin in HL-1 myocytes and at myofilaments in human 
atrial myocytes. Such binding would be in line with previous studies in human and rat 
heart (14,17) and suggest that by binding to contractile proteins, Hsp27 stabilizes 
myofibrils during AF similar to the observed Hsp27-mediated protection of cytoskeletal 
and contractile elements after heat or ischemic stress in myocardium and smooth muscle 
cells (15 ,19,33). Alternatively, binding of Hsp27 to contractile proteins may shield them 
from cleavage by cystein proteases. Cystein proteases are known to become activated 
during AF and result in cleavage of myofilamental proteins (20,28,34,35). Finally, Hsp27 
may accelerate the recovery of myofilamental proteins after disruption, similar to its 
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action on accelerating actinrepolymerization (19). 
Hsp27 expression in paroxysmal and persistent AF 
In atrial tissue of AF patients, Hsp27 expression was only significantly elevated in atrial 
tissue from paroxysmal AF patients and not in persistent AF patients. Moreover, in 
paroxysmal and persistent AF, the variation in Hsp27 levels was large and found to be 
inversely correlated with duration of AF and with the amount of myolysis. Generally 
speaking, upregulation of heat shock proteins in response to a stressful event depends 
both on the intensity and duration of the stress. While it is known that the magnitude of 
the response is dependent on the degree of stress (36), inevitably, the response gets 
exhausted in time if the stress continues (37). Given these features of the heat shock 
response and the antimyolytic effect of Hsp27 in tachy-paced myocytes, the patient data 
may be interpreted as follows. For intermittent periods of stress, such as paroxysmal AF 
in which arrhythmias are separated by non-stressful intervals of normal sinus rhythms, 
myocytes are capable of increasing Hsp levels, which might prevent myofibril disruption. 
As a result, patients with paroxysmal AF may be able to overcome AF paroxysms 
without the induction of structural changes such as myolysis. The observed inverse 
correlation between Hsp27 levels and duration of persistent AF and paroxysmal AF 
suggests that the heat shock response gets exhausted in time, leading to a loss of its 
protective effects, thereby promoting the progression to persistent AF. Indeed, it is shown 
that the heat shock response gets temporarily activated in acute but not in chronic 
diseases (30), during cardiac differentiation (38), and it attenuates with age (37). 
In our study, patients in sinus rhythm with underlying coronary artery disease or mitral 
valve disease were used. Previously, it was described that Hsp27 levels in failing hearts 
were significantly increased compared to normal hearts (39). This would suggest that the, 
in the present study, observed increase in Hsp27 levels in patients with paroxysmal AF 
compared to control patients in sinus rhythm but without underlying heart diseases would 
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be even more significant. Furthermore, the NYHA class I was significantly different in 
both patients with paroxysmal and persistent AF compared to SR patients, and also more 
patients with persistent AF used digitalis compared to paroxysmal AF and SR patients. 
These differences could potentially have influenced the results on myolysis and Hsp 
levels. 
In summary, the results from both the tachypaced cell model for AF and human AF 
provide evidence that elevated expression of Hsp27 protects myocytes from tachypacing 
induced myolysis. The Hsp response that gets temporarily activated in patients with AF, 
seems to exhaust in time, thereby losing the ability to prevent structural changes like 
myolysis, thus leading to the progression of AF. Future experiments are therefore 
warranted to identify the therapeutic usefulness of drugs that boost the Hsp response, 
such as GGA, in AF. 
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Chapter 4 
Abstract 
Background: We previously demonstrated the small heat shock protein, HSPBl, to 
prevent tachycardia remodeling in in vitro and in vivo models for Atrial Fibrillation (AF). 
To gain insight into its mechanism of action, we examined the protective effect of all 10 
members of the HSPB family on tachycardia remodeling. Furthermore, modulating 
effects of HSPB on RhoA GTPase activity and F-actin stress fiber formation were 
examined, as this pathway was found of prime importance in tachycardia remodeling 
events and the initiation of AF. 
Methods and Results: Tachypacing ( 4Hz) of HL-1 atrial myocytes significantly and 
progressively reduced the amplitude of Ca2+ transients (CaT). In addition to HSPB 1, also 
overexpression of HSPB6, HSPB7 and HSPB8 protected against tachypacing-induced 
CaT reduction. The protective effect was independent of HSPB 1. Moreover, tachypacing 
induced RhoA GTPase activity and caused F-actin stress fiber formation. The ROCK 
inhibitor Y27632 significantly prevented tachypacing-induced F-actin formation and CaT 
reductions, showing that RhoA activation is required for remodeling. Although all 
protective HSPB members prevented the formation of F-actin stress fibers, their mode of 
action differs. Whilst HSPB 1, HSPB6 and HSPB7 acted via direct prevention of F-actin 
formation, HSPB8-protection was mediated via inhibition ofRhoA GTPase activity. 
Conclusion :  Overexpression of HSPBl, as well as HSPB6, HSPB7 and HSPB8 
independently protect against tachycardia remodeling by attenuation of the RhoA GTPase 
pathway at different levels. The cardioprotective role for multiple HSPB members 
indicates a possible therapeutic benefit of compounds able to boost the expression of 
single or multiple members of the HSPB family. 
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Introduction 
Atrial Fibrillation (AF) is the most common sustained and progressive clinical 
tachycardia in the population and it significantly contributes to cardiovascular morbidity 
and mortality ( 1 ). AF is characterized by specific changes in electrical, structural and 
conctractile function of the atrial myocytes, commonly denoted as ' remodeling ' . 
Tachycardia remodeling underlies contractile dysfunction and the progressive and 
intractable nature of AF. Therefore, remodeling is believed to have important therapeutic 
implications, and there is great interest in developing anti-remodeling therapies directed 
at the targets underlying remodeling (1). 
We recently identified one specific member of the heat shock protein (HSP) family, 
HSPBl ,  to protect against AF-induced remodeling (2,3). HSPs are molecular chaperones 
and prevent the accumulation of the misfolded or unfolded proteins in the cells ( 4). 
HSPBl is one member of the small heat shock protein (sHSP or HSPB in mammals) 
family, which comprises a total of at least ten members (5 ,6). A characteristic of most 
HSPBs is their ability to interact with components of the actin cytoskeleton, and this 
binding protects against cytoskeletal injury during stress, resulting in conservation of the 
cell function (7). In addition, HSPBs collectively share important features, including <1> 
a conserved a -crystallin domain, <2> ability to form large oligomers in vitro and <3> 
increased expression upon exposure to various stresses including heat stress (8). 
Nevertheless, the precise mode of action of HSPB 1 to protect from tachycardia 
remodeling remains elusive and it is unknown whether this is shared between other 
members of the HSPB family. Therefore, we examined if, in addition to HSPBl ,  also 
other HSPB members protect against atrial tachycardia remodeling. Hereto, we utilized 
tachypaced HL-1 myocytes, an in vitro atrial cell line model for tachycardia remodeling 
(3,9). In addition to HSPB 1, we identified HSPB6, HSPB7 and HSPB8 to protect against 
tachypacing-induced calcium transient reduction. Because of the known protective 
actions of HSPBs on actin cytoskeleton, we next examined their effect on 
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tachypacing-induced RhoA GTPase pathway, including RhoA GTPase activity and 
related F-actin stress fiber formation. Although all protective HSPB members reduced the 
formation of F-actin stress fibers, their mode of action differs. HSPB 1, HSPB6 and 
HSPB7 were found to directly prevent F-actin stress fiber formation, whereas 
HSPB8-protection was mediated via inhibition of upstream RhoA GTPase activi ty. 
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Materials and Methods 
HL-1 atrial myocyte culture, transfections and constructs 
HL-1 atrial myocytes, derived from adult mouse atria, were obtained from Dr. William 
Claycomb as described before (3). The myocytes were maintained in Complete 
Claycomb Medium (JRH, UK) supplemented with 100 µM norepinephrine (Sigma, The 
Netherlands), 0.3 mM L-ascorbic acid (Sigma), 4 mM L-glutamine (Gibco, The 
Netherlands) and 10% FBS (Life Technologies, Gaithersburg, MD). They were cultured 
on coverslips coated with 12. 5 µg/ml fibronectin (Sigma) and 0.02% gelatin (Sigma), in a 
5%  CO2 atmosphere at 37° C. 
To study the influence of HSPBs on Ca2+ transient changes, HL-1 myocytes were 
transiently ( co-)transfected, by the use of Lipofectamin (Life Technologies, The 
Netherlands), with the plasmid CD8 cDNA encoding CDS antigen and/or 
pCDNA5/FRT/TO-HSPBX (X indicating 1-10) encoding human HSPB members. 
Positive myocytes were selected by anti-CDS Dynabeads (Dynal). To check 
overexpression of HSPBX proteins in HL-1 myocytes, myocytes were transiently 
transfected with the fusion proteins V5-HSPBX. For all other experiments HSPBX 
wildtype constructs were used. 
Tachypacing of HL-1 myocytes 
HL-1 myocytes were subjected to tachypacing as described before (2,3,9). In short, the 
spontaneous rate of HL-1 myocytes is ~ 1 Hz. HL-1 myocytes were subjected to normal 
electrical field stimulation (1 Hz) for at least 30 min before tachypacing via the 
C-PacelO0™-Culture Pacer (IonOptix Corporation, The Netherlands). Tachypacing was 
performed at 4 Hz with 20-ms pulses for S hours to induce CaT reduction and 1 Hz 
pacing was used as a control. 
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Protein-extraction and Western blot analysis 
Western-blot analysis was performed as described previously (2,3). Equal amount of 
protein in SOS-PAGE sample buffer was sonicated before separation on I 0% PAA-SOS 
gels. After transfer to  nitrocellulose membranes (Stratagene, The Netherlands), 
membranes were incubated with primary antibodies against HSPB I (SP A80 I ,  StressGen 
USA), VS tag (Invitrogen, The Netherlands) or GAPOH (Affinity Reagents, The 
Netherlands). Horseradish peroxidase-conjugated anti-mouse or anti-rabbit (Santa-Cruz 
Biotechnology, The Netherlands) was used as secondary antibody. S ignals were detected 
by the ECL-detection method (Amersham, The Netherlands) and quantified by 
densitometry . 
Live imaging and measurement of CaT 
To measure CaT, 2µM of the Ca2+-sensitive Fluo-4-AM dye (Invitrogen, The 
Netherlands) was loaded into HL-1 myocytes by 45 min incubation, followed by 3 times 
washing with DMEM solution. Ca2+ loaded myocytes were excited by 488 nm and light 
emitted at 5 00-5 50  nm and visually recorded with a 40x-objective, using a 
Solamere-Nipkow-Confocal-Live-Cell-Imaging system (based on a Leica OM IRE2 
Inverted microscope). The live recording of CaT in HL-1 myocytes was performed at 
I Hz of stimulation in a temperature (37°C) controlled system. By use of the software 
ImageJ (National Institutes of Health, USA), the absolute value of fluorescent signals in 
live myocytes were recorded and analyzed. To compare the fluorescent signals between 
experiments, the following calibration was utilized: Fcai=F/F0, in which (F) is fluorescent 
dye at any given time and (F0) is fluorescent signal at rest (10). Mean values from each 
experimental condition were based on 7 consecutive CaT in at least 5 0  myocytes. 
Immunofluorescent staining and confocal analysis 
Twenty-four hours after transient transfection of HSPBl, HSPB5, HSPB6, HSPB7 and 
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HSPB8, HL-1 myocytes were subjected to (tachy)pacing. Afterwards, the myocytes were 
fixed with 3. 7% formaldehyde for 15 minutes, washed three times with 
Phosphate-Buffered Saline (PBS), permeabilized with 0.2% Triton-Xl00 and blocked 
with 0.1 glycine (10 minutes at room temperature) and 5 %  BSA (30 minutes at room 
temperature). Antibodies against HSPB6, HSPB7 and HSPB8 (all Abeam, The 
Netherlands), and HSPBl and HSPB5 (StressGen, USA) were used as primary antibody. 
Fluorescein labeled isothiocyanate (FITC) anti-mouse or anti-rabbit (Jackson 
ImmunoResearch, The Netherlands) were used as secondary antibodies. To visualize 
F-actin, rhodamine phalloidin (Invitrogen, The Netherlands) was diluted with PBS at 1 :40, 
followed by incubation for 20 minutes at room temperature and washed three times with 
PBS. Images of FITC and rhodamine fluorescence were obtained using the Leica 
confocal laser scanning microscope (Leica SP2 AOBS) with 63X/l .4 oil lens. The 
captured images were processed using Leica Confocal Software and Adobe Photoshop. 
For determination of the amount of F-actin stress fibers, the intensity of fluorescence was 
analyzed by ImageJ in 5 independently taken fields. HL-1 myocytes were treated 4 hours 
prior and during (tachy)pacing with the ROCK inhibitor Y27632 (1 0µM, Sigma, The 
Netherlands) to prevent F-actin stress fiber formation. For determination of the amount of 
colocalization of HSPB with stress fibers, ImagePro software was used. The amount of 
colocal ization was determined as the ratio of total red signal (F-actin) divided by yellow 
signal (colocalization HSPB with F-actin). Between 400 and 500 myocytes were 
quantified per condition. 
Short interfering RNA of HSPBl in combination with over-expression of HSPB6, 
HSPB7 or HSPBS 
Downregulation of endogenous HSPB 1 was performed as described previously (3 ). 
HL-1 myocytes were transiently transfected with HSPB I siRNA or mock constructs for 5 
days. Furthermore, 24 hours before tachypacing, cells were co-transfected with HSPB6, 
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HSPB7 or HSPB8 construct. After 8-hours (tachy)pacing, CaT were measured and 
analyzed. 
RhoA GTPase activity measurement with G-LISA 
For the quantitative analysis of active RhoA GTP levels, G-LISA RhoA Activation Assay 
(Cytoskeleton, USA) was performed according to the manufacturer protocol. Briefly, 48 
hours after the transfection of HL-1 myocytes, myocytes were subjected to (tachy)pacing 
for 6 hours or directly lysed in lysis buffer and cells were harvested. After measurement 
of the protein concentration with the use of Precision Red (supplied), equal amounts of 
lysates were incubated in RhoA GTP affinity plates. The amount of bound RhoA GTP 
was detected by using primary anti-RhoA antibody (1 :250, supplied) and secondary 
HRP-labeled antibody (1 :62. 5 ,  supplied). Colorimetric detection at 490nm was performed 
immediately (BioRad, The Netherlands). 
Actin ( de-)polymerization-assay 
To determine the direct effect ofHSPBs on actin polymerization and depolymerization an 
actin polymerization biochem kit (Cytoskeleton, USA) was used. Twenty-four hours after 
transient transfection of HL-1 myocytes with HSPBI , HSPB5, HSPB6, HSPB7 or 
HSPB8, myocytes were lysed in a mild lysis buffer according to the manufacturer 
protocol . As a control, recombinant human HSPB I (Stressgen, USA) was dissolved in 
lysis buffer. Base-line fluorescence of pyrene conjugated actin was measured (Ex. 350 
nm; Em. 405 nm) for three minutes, after which cel l lysates and recombinant HSPB I 
were added to measure effect on ( de-)polymerization. Fluorescence was assayed every 60 
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Results are expressed as mean ± SEM. All CaT measurements were performed in at least 
triple series. Mean values from each experimental condition were based on 7 consecutive 
CaT in at least 50  myocytes. ANOV A was used for multiple-group comparisons. All 
p-values were two-sided. P<0.05 was considered statistically significant. SPSS version 
16.0 was used for statistical evaluation. 
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Figure 1 HSPB 1 ,  HSPB6, HSPB7 and HSPB8 overexpression prevents against 
tachypacing-induced CaT reductions in HL-1  myocytes. (A) Representative Western blot showing 
overexpression of HSPB 1 - 1 0  in transiently transfected HL- 1  myocytes. (B) Original recordings of 
CaT in 1 myocyte each from groups indicated. (C) Mean CaT data of HSPB 1 - 1 0  overexpressing 
myocytes tachypaced (4 Hz) or normal paced cells (I Hz). **P<0.01 ,  ***P<0.00 1 vs control 




Effect of overexpression of the ten different HSPB members on tachypacing-induced 
remodeling in HL-1 myocytes. 
In humans, the HSPB family comprises a group of 10 members with monomeric 
molecular weight varying between 16 to 28 kDa (5 ,6,8). Induction of HSPB 1 has been 
shown previously to protect against atrial tachypacing-induced remodeling, including 
CaT reduction (3). To study the effect of individual HSPB members, HL-1 myocytes 
were transfected with VS tagged constructs for each member. All members were 
successfully overexpressed, albeit HSPB8 and HSPB9 at a lower level (Figure IA). As a 
control group, HL-1 myocytes were transfected with an empty vector. None of the 
overexpressed HSPB members changed CaT in control myocytes paced at lHz (data not 
shown). As observed before (3), tachypacing at 4Hz of HL-1 myocytes resulted in a 
significant and progressive reduction in CaT (SI Figure S 1 ), which was attenuated by 
HSPB 1 (Figure lB,C SI movies S 1-3). In addition, overexpression of HSPB6, HSPB7 
and HSPB8 also protected against tachypacing-induced CaT depression, whereas the 
other members were ineffective (Figure lB,C and SI movies S l -12). These results 
indicate that in addition to HSPB 1 also HSPB6, HSPB7 and HSPB8 protect against 
tachypacing-induced CaT reduction. 
HSPB6, HSPB7 and HSPB8 protection against tachypacing-induced CaT reduction 
is independent of endogenous HSPBl expression. 
HSPB members are known for their ability to form hetero-oligomeric complexes ( 11, 12) 
and given the fact that HSPB 1 is constitutively expressed in HL-1 myocytes, the 
possibility existed that the protective effect of HSPB6, HSPB7 or HSPB8 on 
tachypacing-induced CaT reduction was related to (indirect) effects via 
( oligomerization with) HSPB 1. Also, ectopic HSPB expression may induce a stress 
response in cells leading to the up-regulation of endogenous HSPB 1. To exclude these 
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possibilities, it was first determined whether overexpression of HSPB6, HSPB7 or 
HSPB8 increased expression of endogenous HSPB 1 levels. As shown in Figure 2, 
endogenous HSPBI levels were similar after normal pacing (lHz) and tachypacing (4Hz), 
irrespective of HSPB6, HSPB7 or HSPB8 overexpression. Secondly, the endogenous 
HSPB I level was suppressed by short hairpin RNAs (Figure 3A). In HSPB 1 depleted 
myocytes, HSPB6, HSPB7 or HSPB8 overexpression could still protect against 
tachypacing-induced CaT reduction (Figure 3B,C, SI movies S13-18). In summary, these 
results suggest that the protective effects of HSPB6, HSPB7 and HSPB8 against 
tachypacing-induced CaT reduction are independent of HSPB 1. 
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Figure 2 Overexpression of HSPB6, HSPB7 or HSPB8 do not result in changes in endogenous 
HSPB l levels. (A) Representative Western blot showing that the endogenous HSPB 1 levels in 
transfected HSPB6, HSPB7 and HSPB8 overexpressing HL-1 myocytes are not changed in normal 
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Figure 3 HSPB6, H SPB7, HSPB8 protective effect is independent of HSPB 1 .  (A) Western blot 
showing efficient siRNA-induced HSPB I knockdown in HL- 1 mycoytes. (B) Recordings of CaT for 
mock and siRNA construct. HL- 1 myocytes were transfected with mock or siRNA construct for 5 
days before study. One day before tachypacing, the myocytes were transfected with HSPB6, HSPB7 
or HSPB8 and subjected to normal pacing ( 1  Hz) or tachypacing (4 Hz). (C) Mean CaT data. The 
cardioprotective effect of HSPB6, HSPB7 or HSPB8 was not blocked by HSPB 1 suppression. 
*** P<0.00 I vs control tachypaced ( 4 Hz). # P<0.00 1 vs control normal paced ( I Hz). 
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HSPB6, HSPB7 and HSPB8 reduce the amount of F-actin stress fibers after 
tachypacing in HL-1 myocytes. 
Calcium signaling is known to be markedly influenced by the stabilization of the 
cytoskeleton ( 1 3-1 5 ). F-actin is one of the major components of the cytoskeleton and 
located under the plasma membrane to maintain cell shape, rigidity and integrity ( 16, 1 7). 
Several HSPB members, including HSPBl , HSPB5, HSPB6, HSPB7 and HSPB8, have 
been reported to be involved in cytoskeletal stability ( 1 8-21 ). To study if the underlying 
mechanism for HSPB protection is related to effects on actin, immunofluorescent 
staining was performed. We observed a 1 . 7  fold induction in the amount ofF-actin stress 
fibers in tachypaced HL-1 myocytes compared to normal paced control myocytes 
(Figure 4, SB), an effect that was significantly reduced by overexpression of HSPBl , 
HSPB6, HSPB7 or HSPB8 (Figure 5 A,B). Overexpression of HSPB5, which did not 
show protection against tachypacing-induced CaT reductions (Figure 1 ), also did not 
lead to a reduction in the amount of tachypacing-induced F-actin stress fibers (Figure 4, 
SB). Although in tachypaced HSPB 1 ,  HSPB6, HSPB7 or HSPB8 overexpressing 
myocytes a reduction in the amount of F-actin stress fibers was found, HSPB 1 ,  HSPB6, 
HSPB7 and to a lesser extent HSPB8 colocalized with the F-actin residues after 
tachypacing and this was not the case for HSPB5 (Figure 4, 5 A,C). Taken together, 
these results suggest that HSPBl , HSPB6, HSPB7 and HSPB8 prevent the formation of 
F-actin stress fibers in tachypaced HL-1 myocytes, and thereby stabilize the 
cytoskeleton and myocyte function. 
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HSPBl pcDNA HSPBl HSPB6 HSPB7 HSPB8 HSPBS 
Figure 4 HSPB I ,  HSPB6 and HSPB7  coocalize with tachypacing-induced F-actin stress fibers in 
HL- 1  myocytes.lmmunofluorescent staining of F-actin stress fibers (red) and HSPB positive 
myocytes (green), in tachypaced HL-1 myocytes ( 4 Hz). A normal paced (1 Hz) HSPB 1 transfected 










































ro o �  ...................... _._...,..,_...,_._ ....... ._.__�.,..,_ ............... � 
Figure 5 HSPBl .  HSPB6, HSPB7 and HSPB8 overexpression is associated with a reduction in the 
amount of tachypacing-induced F-actin stress fibers in HL-1 myocytes. (A) lmmunofluorescent 
staining of F-actin stress fibers (red) and HSPB7 positive myocytes (green), in tachypaced HL- 1 
myocytes (4 Hz). HSPB7 positive myocytes reveal less stTess fibers. (B) Quantification of the 
amount of F-actin stress fibers in HSPB transfected HL- 1 myocytes after nonnal pacing ( 1  Hz) or 
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tachypacing ( 4 Hz). (C) Quantification of the amount of colocalization of transfected HSPB with 
F-actin stress fibers. *P<0.05, **P<0.0 1 ,  ***P<0.00 1 vs control tachypaced myocytes (4 Hz), 
#P<0.05 vs control normal paced (1 Hz). 
Tachypacing induces RhoA GTPase and ROCK activation, resulting in F-actin 
formation and reduction in calcium transients. 
To confirm the role of RhoA GTPase pathway in tachypacing-induced F-actin stress fiber 
formation and reductions in CaT, HL-1 myocytes were tachypaced for 0-8 hours and 
RhoA GTPase activity was measured in cell lysates (Figure 6A). A significant induction 
of the RhoA GTPase activity was observed at 6 hours of tachypacing. In parallel, the 
amount of F-actin was quantified. A gradual increase in the amount of F-actin was 
observed during tachypacing, which was prevented by the ROCK inhibitor Y27632 
( IOµM) (Figure 6B). In addition, also tachypacing-induced changes in CaT were reduced 
by Y27632 (Figure 6C), indicating that also this effect is RhoA-mediated. 
HSPB8, but not HSPBl, HSPB6, and HSPB7, reduces activation of RhoA GTPases 
after tachypacing 
To test whether the protective effect of HSPB members is related to a direct modulation 
of the RhoA GTPase activity, RhoA GTPase activity was measured in normal paced ( !Hz) 
and tachypaced ( 4Hz) HL-1 myocytes transfected with the individual HSPB members. 
None of the HSPB members affected RhoA GTPase activity in l Hz paced HL-1 
myocytes (SI Figure S2). Only HSPB8 transfected HL-1 myocytes revealed significantly 
reduced activation of RhoA GTPase upon 6 hours of tachypacing and all other (protective) 
HSPB members were ineffective (Figure 7), suggesting that their protective effects 
against tachycardia remodeling are downstream of RhoA GTPase activation. 
HSPBl, HSPB6, and HSPB7 prevent G-to-F actin polymerization. 
To investigate whether HSPBl, HSPB6, and HSPB7, rather than affecting RhoA GTPase 
activation, may ameliorate the downstream consequences of activated RhoA GTPase, we 95 
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measured their effect on the polymerization of G-actin to F-actin and also the 
depolymerization, using an in vitro polymerization kit. Base-line fluorescence of 
G/F-actin ratios were measured for three minutes, after which cell lysates from HL-1 
myocytes transfected with the respective HSPB members or recombinant HSPB l were 
added (Figure 8). The non-protective HSPB5 was used as a control. When polymerization 
buffer was added to the baseline G/F-actin, a rapid increase in the conversion of G-to-F 
actin ratio was observed, indicative of fast actin polymerization. Addition of lysates from 
HSPB 1 transfected cells as well the addition of 0.5µg recombinant human HSPB 1 
induced depolymerization of F-actin. Although less effective, lysates from HSPB6 also 
induce depolymerization, whereas lysates from HSPB7 transfected myocytes prevent 
actin polymerization but did not show an effect on depolymerization. In contrast to the 
findings of HSPB 1, HSPB6 and HSPB7 in preventing the formation and/or stimulating 
the depolymerization of F-actin stress fibers, addition of lysates from HSPB8 transfected 
cells resulted in actin polymerization, although the levels of polymerization were reduced 
compared to lysates of the non-protective HSPB5 transfected myocytes, which showed 
near to normal polymerization. 
These results together suggest that HSPB 1, HSPB6 and HSPB7 may prevent tachycardia 
remodeling by directly preventing the formation and/or stimulating the depolymerization 
of F-actin stress fibers downstream of active RhoA GTPase, whilst HSPB8 mainly acts at 
the level of tachypacing-induced RhoA GTPase activation. 
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Figure 6 Tachypacing induces gradual activation of RhoA-GTPase and consequently formation of 
F-actin stress fibers and reduction in CaT in HL- 1 myocytes. (A) HL-1 myocytes were tachypaced 
upto 8 hours and activation of RhoA-GTPase was measured. (B) Left: Examples of 
immunofluorescent staining of F-actin stress fibers (red) in tachypaced HL-1 myocytes (4 Hz, 4 
and 8 hours), normal paced (I Hz) and tachypaced HL-1 myocytes pretreated with the ROCK 
inhibitor Y27632 ( 4 Hz, 8 hours). Right: quantification of the fluorescence intensity of F-actin in 
the conditions as indicated. (C) Top: Original recordings of CaT in I myocyte each from groups 
indicated. Below: Mean CaT data of normal (I Hz) and tachypaced (4 Hz) HL-1 myocytes and 
tachypaced myocytes pretreated with Y27632. ***P<0.001 Y27632 tachypaced vs control 
tachypaced (4 Hz), #P<0.001 vs control normal paced (I Hz). 
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Figure 7 HSPB8 reduces activation of RhoA-GTPase during tachypacing in HL-1  myocytes. HL- 1 
myocytes were transfected with HSP B l .  HSPB5. I ISPB6. HSPB7. HSPB8. or empty plasmid 
(pcDNA) and subjected to tachypacing (4 Hz, 6 hours). Activation ofRhoA-GTPase in tachypaced 
( 4 I lz) HL-1 myocytes. tnmsfected with plasmids as indicated. is shown. * P<0.05 vs control 
tachypaced myocytes (4 Hz). 
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Figure 8 HSPB 1. HSPB6. and HSPB7 attentuate F-actin stress fiber formation in vitro. Cel l-lysates 
from HL-1 myocytes transfected with HSPB I ,  HSPB5.  HSPB6. HSPB7, or HSPB8 and 
recombinant human HSPB I were used to measure influence of HSPB members on polymerization 
of G-actin to F-actin and also the depolymerization. ** P<0.01 vs lysates of HSPB5 transfected 
myocytes at 20 minutes incubation. *** P<0.001 vs lysates of HSPB5 transfected myocytes at 20 
minutes incubation. 
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Discussion 
Previously, we showed HSPB 1 to protect in HL-1 myocytes against tachycardia 
remodeling and to preserve normal Ca2+ transients as well as the actin cytoskeleton upon 
tachypacing (2,3). In the current study we found that, in addition to HSPB 1, also some 
other members of the HSPB family (HSPB6, HSPB7 and HSPB8) display protective 
effects against tachypacing-induced remodeling. Interestingly, all protective HSPB 
members reduced the formation of F-actin stress fibers, although their modes of action 
differ. Whereas HSPB8 interfered with tachypacing-induced RhoA GTPase activity, 
HSPBI, HSPB6, and HSPB7 did not. HSPBI, HSPB6 and HSPB7 were found to directly 
inhibit G- to F-actin polymerization and/or stimulate depolymerization, indicating a 
protective role against tachycardia remodeling downstream of RhoA GTPase activation. 
Role of Rho GTPases in induction of AF 
The current study revealed a prime role for tachypacing-induced RhoA GTPase activity 
and consequently F-actin stress fiber formation in reductions in calcium transients. This 
finding is in line with studies revealing an important role for Rho GTPases, including 
RhoA and Rae l ,  in formation ofF-actin stress fibers (22) and the initiation of AF (23,24). 
Consistently, experimental studies showed that activation of RhoA GTPases result in 
conduction disturbances and cardiac dysfunction similar to those described in AF (25 ,26). 
Rho GTPases represent a family of small GTP-binding proteins involved in cell 
cytoskeleton organization, migration, transcription, and proliferation. Rho GTPases have 
gained considerable recognition as powerful regulators of actin cytoskeletal organization 
in the heart (22). It was observed that active Rho GTPases stimulate the conversion of 
G-actin to F-actin, which results in cytoskeletal injury including changes in calcium 
signaling, conduction disturbances and contractile dysfunction (13-16), which are all 
substrates for the development of AF (25 ,26). Actin stress fiber assembly and contraction 
are predominantly mediated by Rho-associated serine/threonine kinase (ROCK), a major 
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down-stream effector of the Rho pathway. Consistent with all of the above, we now show 
that tachypacing activates RhoA and that inhibition of ROCK, its effector of actin 
polymerization, prevents tachypacing-induced reductions in CaT. 
The HSPB family 
Whereas all HSPB members are characterized by the presence of a conserved crystallin 
domain, this domain is flanked by N- and C-termini that shows large sequence divergence 
between the members (Table 1) (5 ,8). Also, the four members (HSPB 1, HSPB6, HSPB7 
and HSPB8) that we found to have protective effects against tachycardia remodeling 
show, besides sequence divergence, a number of structural and functional differences (see 
below). Interestingly, however, all four members, together with the non-protective 
HS PBS , show high basal expression in heart tissue (Table 1 ). In addition, three members 
(HSPB I ,  HSPB6, HSPB7) seemed to act similar in AF protection, i.e. preventing actin 
remodeling downstream of RhoA-activation. Only HSPB8 appears to directly affect 
RhoA-activation. So, the question is what are the characteristics shared by these members 
and, in addition, what are the differences between them that can explain their protective 
effects on tachypacing-induced remodeling? 
In cell-free assays, small HSPs have been shown to act as ATP-independent "holdases", 
maintaining unfolded or misfolded proteins in a folding competent, non-aggregated state, 
hereby supporting refolding by ATP-regulated chaperones, in particular the HSP70 
machinery (8). In cellular assays, however, of the four cardioprotective HSPB members, 
only HSPB 1 seems to support such refolding reaction (27 ,28). Moreover, HSPBS also 
shares this activity (28), but did not reveal protective effects against tachycardia 
remodeling. This finding indicates that such a chaperone-like activity is not of prime 
importance to the HSPB-mediated protective effects as reported in the current study. 
Several members of the HSPB family, including HSPB6, HSPB7 and HSPB8 were 
recently shown to be able to assist in the clearance of stress-induced misfolded proteins, 
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in part through interaction with (HSPB7) or activation of (HSPB8) the macro-autophagy 
machinery (28-30). Yet, this activity is not shared by e.g. HSPB 1 whilst HSPB9 that also 
can enhance clearance of misfolded proteins (28), albeit likely via proteasomal 
degradation (31) had no effect on AF. So, the clearance of misfolded proteins seems not 
to be a common target of all cardioprotective HSP members. 
Another feature shared amongst many HSPB members is their dynamic 
(de)oligomerisation (5 ,8). This characteristic has been suggested to be crucial for e.g. the 
ability of HSPB I to interact with several cytoskeletal components, including actin, 
intermediate filaments, and microtubules (7,32). Yet, in cells HSPB7 and HSPB8 do not 
appear to be present in large oligomeric structures (31,33) implying also that this does not 
edify their protective role against tachycardia remodeling. However, all protective HSPB 
members can be found in cells as non-oligomeric (most likely dimeric) proteins as well. 
For HSPB I ,  dimers have been suggested to be the active species in regulating actin 
(re)polymerization after stress (34). Also for HSPB6 stress-induced translocation to actin 
of the myofibrils has been reported, which has been associated with improved heart 
function (32). Also HSPB7 translocates from cytosol to the Z-/I-area of myofibrils, and 
thereby exerts a protective effect to ischemic stress (21 ). This interaction may be 
mediated via a-filamin, an actin-binding protein (35). All of this is consistent with our 
current findings that HSPBI , HSPB6 and HSPB7 are associated with F-actin stress fibers 
upon tachypacing and the fact that they can directly prevent actin polymerization, an 
effect that occurs in living cells as a down-stream effect of Rho activation. In addition, 
the findings also suggest that chaperone-like (refolding or clearance) function and actin 
protection are distinct, uncoupled functions of these HSPB members. For HSPB8, the 
remaining AF protecting HSPB member, no direct association with actin and/or 
microtubules has been reported so far. Although HSPB8 is highly expressed in heart and 
muscle and anti-HSPB8 antibodies decorate sarcomeres (30), only a weak association 
with F-actin stress fibers after tachypacing was observed in the current study. Moreover, 
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we only found weak attenuating effects of HSPB8 on actin polymerization. So, the 
protective effects of HSPB8 against tachycardia remodeling seem distinct from that of the 
other HSPB members. Consistently, we indeed observed that HSPB8 was the only 
member that directly affected tachypacing-induced RhoA activation. How HSPB8 may 
modulate this effect remains an enigma, but maybe its unique role within the HSPB 
family in activating autophagy (28,29) may be important. Autophagy may prevent protein 
aggregate formation that served as an early trigger for RhoA activation. Indeed, 
preventing aggregate formation has been suggested as the mode by which HSPB8 can 
prevents desmin-related cardiomyopathy (36). 
The present study demonstrates that RhoA activation plays a central role in 
tachypacing-induced myocyte remodeling. This remodeling can be prevented by some, 
but not all, members of the HSPB family. This protection is not directly related to 
canonical chaperone-like function of these HSPB members, but involves prevention of 
RhoA activation (HSPB8) or its downstream action on actin remodeling (HSPB 1, 
HSPB6, HSPB7). The findings widen the possibilities for the identification of novel 
therapeutic approaches directed at RhoA activating components or boosting the 
expression of one or more of the cardioprotective HSPB members. 
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Abstract 
The most common clinical tachycardia, Atrial Fibrillation (AF), is a progressive disease, 
caused by cardiomyocyte remodeling, which finally results in contractile dysfunction and 
AF persistence. Recently, we identified a protective role of heat shock proteins (HSPs ), 
especially the small HSPB 1 member, against tachycardia remodeling in experimental AF 
models. Our understanding of tachycardia remodeling and anti-remodeling drugs is 
currently hampered by the lack of suitable (genetic) manipulatable in vivo models for 
rapid screening of key targets in remodeling. We hypothesized that Drosophila 
melanogaster can be exploited to study tachycardia remodeling and protective effects of 
HSPs by drug treatments or by utilizing genetically manipulated small 
HSP-overexpressing strains. Tachypacing of Drosophila pupae resulted in gradual and 
significant cardiomyocyte remodeling, demonstrated by reduced contraction rate, 
increase in arrhythmic episodes and reduction in heart wall shortening, compared to 
normal paced pupae. Heat shock, or pre-treatment with HSP-inducers GGA and BGP-15 , 
resulted in endogenous HSP overexpression and protection against tachycardia 
remodeling. DmHSP23 overexpressing Drosophilas were protected against tachycardia 
remodeling, in contrast to overexpression of other small HSPs (DmHSP27, DmHSP67Bc, 
DmCG446 l, DmCG 7 409, DmCG 14207). (Ultra)structural evaluation of the tachypaced 
heart wall revealed loss of sarcomeres and mitochondrial damage which were absent in 
tachypaced DmHSP23 overexpressing Drosophila. In addition, tachypacing induced a 
significant increase in calpain activity, which was prevented in tachypaced Drosophilas 
overexpressing DmHSP23 . Tachypacing of Drosophila resulted in cardiomyocyte 
remodeling, which was prevented by general HSP-inducing treatments and 
overexpression of a single small HSP, DmHSP23 . Thus, tachypaced Drosophila 
melanogaster can be used as an in vivo model system for rapid identification of novel 
targets to combat AF associated cardiomyocyte remodeling. 
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Introduction 
Atrial Fibrillation (AF) is the most common tachycardia in the clinical setting and it 
affects patients' cardiovascular function in a progressive and sustained manner (1). AF is 
characterized by specific changes in electrical, structural and contractile function of the 
atrial cardiomyocytes, commonly denoted as ' remodeling' . Tachycardia remodeling 
underlies contractile dysfunction and the progressive and intractable nature of AF (2). 
Hence, there is great interest in developing anti-remodeling therapies directed at the 
targets underlying remodeling (3). However, our understanding of tachycardia 
remodeling that contributes to AF progression and the effects of anti-remodeling drugs is 
currently hampered by the lack of suitable genetically manipulatable in vivo models. 
There are some in vitro cardiomyocyte cell models, using isolated atrial cardiomyocytes 
or the HL-1 atrial cardiomyocyte cell line ( 4,5 ), that can be used for such purposes and 
that yielded initial suggestions regarding the protective effects of heat shock proteins 
(HSPs) ( 4,6, 7). Whereas some of the concepts generated in these in vitro models could be 
confirmed in experimental canine models for AF ( 4,8), the precise translation to the in 
vivo situation is hindered due to limited possibilities for genetic manipulations in 
experimental models (9) and larger animal models that beside canine models (10), 
include AF models in goat (11) and sheep (12). Although these animal models have been 
very useful in obtaining knowledge about concepts of electrical remodeling and 
contractile dysfunction, they lack the flexibility of dissecting the underlying molecular 
mechanisms and employing genetic or compound screens. In addition, experimental 
execution is extensive and expensive. Therefore, we utilize Drosophila melanogaster as 
an in vivo model system for tachycardia remodeling, since it has been recognized that 
Drosophila contains powerful genetics and provide tools to manipulate gene expression 
in a highly precise spatial and temporal fashion, by the use of a UAS/GAL4 system 
(13,14). Furthermore, 85% of the Drosophila genes have human homologues (13,15 , 16), 
including several genes that have been associated with human cardiac diseases, including 
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heart failure, arrhythmias and dilated cardiomyopathy (14, 15 , 17-20). Moreover 
Drosophila contains a pumping heart (13-16). In the current study we report on the 
development of a tachycardia model in Drosophila. In addition, we show, consistent with 
our previous findings in in vitro cardiomyocytes ( 4,6) and in vivo canine models for AF 
(4,8), that induction of HSPs protects against tachypacing-induced contractile dysfunction. 
Furthermore, by using both functional and (ultra)structural analyses, it was found that this 
protection is accomplished upon overexpression of a single HSP, DmHSP23, the possible 
ortholog of human HSPB 1. Moreover, overexpression of the other small DmHSP 
members did not result in a protective effect. Thus our study demonstrates the feasibility 
and power of the tachypaced Drosophila melanogaster as a model in translational 
research in the field of tachycardia induced heart failure. 
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Materials and Methods 
Maintenance of Drosophila melanogaster strains and HSP-inducing treatments 
Drosophila stocks were maintained at 21 °C, during experiments at 25°C, according to 
standard protocols. The WI 118 line was used as a control and obtained from Genetic 
Services Inc. (Massachusetts, USA). Actin-GAL4 (stock #4414) driver strains were 
obtained from the Bloomington Stock Centre (Indiana University, USA). 
UAS-DmHSP23 and UAS-DmHSP27 strains were generated from WI 118 genetic 
background and have been described before (21-23). These UAS strains were crossed, 
using standard genetics, with the actin-GAL4 expressing strains in order to generate 
strains that contain actin-GAL4 and either UAS-DmHSP23 or UAS-DmHSP27 on the 
same chromosome. Stable ubiquitous overexpression of DmHSP23 and DmHSP27 was 
confirmed by Western blotting with specific antibodies. Other Drosophila small HSP 
overexpressing strains included were HSP67Bc, CG4461, CG7409, CG14207 (24,25). 
These transgenic strains were generated at Genetic Services Inc. by injection of the pUAS 
vector containing a small HSP of interest with a V5 tag, into the Wll 18 genetic 
background. These transgenic strains were crossed with actin-GAL4 expressing flies in 
order to induce ubiquitous transgenic gene expression of the small DmHSP of interest in 
the F I  progeny, which was confirmed by Western blotting. 
Heat treatment was performed at 3 7°C for I hour followed by an overnight recovery at 
25°C. The HSP-inducing compounds Geranylgeranylacetone (GGA, lmM) and 
O-(3-piperidino-2-hydroxy-1-propyl)-nicotinic acid amidoxim di-hydrochloride (BGP-15, 
lmM) (both kind gifts from Eisai Japan and NP-gene USA, respectively) were freshly 
dissolved in de-mineralized water and 0.5 ml was added to standard Drosophila food for 
at least 48 hours before (tachy)pacing. Controls were subjected to de-mineralized water 
only. 
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Tachypacing of Drosophila and measurement of heart function parameters 
Early pupae were selected as described before (26). In short, transparent pupae were 
selected at entry of the immobile phase (this phase continues for about 3 hours) and were 
placed on 1 % agarose gel in PBS. The basal heart rate in the early pupae was about 2.2Hz 
(Supplementary information Figure IA). Pupae were tachypaced by using the 
C-Pacel O0™-Culture Pacer (lonOptix Corporation, The Netherlands) for 0-120 minutes. 
Controls were subjected to normal electrical field stimulation similar to basal heart rate 
(2.2Hz) whereas tachypacing was conducted at 2.3 fold basal rate or as indicated. The 
heart wall of pupae could follow the pacing rate (Supplementary information Figure 18). 
During interruption of (tachy)pacing for about 40 seconds, spontaneous heart function at 
each time point was visually scored under the light microscope in duplicate periods of 20 
seconds. In short, the rate of contraction of the heart was quantified by focussing on the 
heart wall contrast edges (26) and only regular contractions were included. During 
(tachy)pacing interruption, also time lapse movies were made and analyzed by edge 
detection software (Leica Microsystems, Mannheim, Germany) to determine the heart 
wall shortening, which indicates the strength of contraction (amplitude of diastolic and 
systolic heart wall contraction), and duration of arrhythmic periods (lmageJ). 
Arrhythmicity index was calculated as the duration of arrhythmic periods divided by the 
total duration of measured periods. 
Quantitative PCR 
From at least five early pupae per condition, total RNA was isolated by utilizing the 
Nucleospin RNA/protein mini kit (Macherey-Nagel, The Netherlands). First strand cDNA 
was generated using M-MLV reverse transcriptase (lnvitrogen, The Netherlands) using 
oligo(dT)l8 primers (Biologio, The Netherlands). Relative changes in transcription level 
were determined using the CFX384 Real-Time System ClO00 Thermocycler (BioRad, 
The Netherlands) in combination with SYBR green supermix (Bio-Rad, The Netherlands). 
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Calculations were performed using the comparative CT method according to User 
Bulletin 2 (Applied Biosystems). Fold induction was adjusted using RpL32 transcript 
levels as a standard. Primer pairs used included the heat inducible DmHSP27 F: 
CTAGACAGGGTTGTGAATAAAGAG and R: AAACCGAAGTCATCCTCCAG and 
DmHSP70AA F: 
AATGAAAGTG 
ACCTCAACCTATCCATCAACC and R: GTCTCAATTCCC 
and for RpL32 F: CGATCTCGCCGCAGTAAA and R: 
GCACCAAGCACTTCATCC. The PCR efficiencies for all primer pairs were between 
85% and 100%. 
Western blot analysis 
Drosophila pupae or adult flies (five per condition) were quickly lysed on ice in 5 0  µl 
SDS sample loading buffer (10% SDS, 50% glycerol, 0.33M Tris-HCl pH 6.8, 10% 
�-mercaptoethanol, 0.05% bromophenol blue) followed by sonification. After a short 
spin-down, supernatant was collected and boiled for 6 minutes. Proteins were separated 
on SDS-PAGE 4-20% Precise™ Protein gels (Thermo Scientific) and transferred onto 
nitrocellulose membranes (GE Healthcare, The Netherlands). The membranes were 
blocked in 5% skim milk (1 hour, room temperature) and incubated overnight at 4°C with 
primary Drosophila anti-DmHSP23, anti-DmHSP27 antibodies (27,28), anti-V5 
antibodies (Invitrogen, The Netherlands) or anti a-tubulin antibodies (Sigma, The 
Netherlands). Horseradish peroxidase-conjugated anti-mouse (Santa-Cruz Biotechnology, 
The Netherlands) was used as secondary antibody. Signals were detected by Super Signal 
(Thermo Scientific, The Netherlands) and quantified by densitometry. 
(Ultra) structural evaluation by Light and Electron Microscopy 
For morphological evaluation, the head and the abdomen were dissected from the early 
pupae and the middle segment was immediately fixed for at least 2 hours at 4°C in 2% 
glutaraldehyde (in 0.lM cacodylate buffer, pH7.4). Post-fixation was performed for 2 
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hours in 1 % osmium tetroxide (supplemented with 1. 5% �Fe(CN)6 in cacodylate buffer, 
pH7.4) at 4°C. After dehydration in ethanol, pupae were embedded in Epon and semi-thin 
sections ( lµm) were cut and stained with 1% toluidine blue and used for light 
microscopic evaluation. To verify the ultrastructural changes, ul trathin sections (60nm) 
were made and stained with uranylacetate and lead citrate and examined in a Philips 
CM 100 electron microscope operating at 60kV. Changes were evaluated in six randomly 
chosen regions by an investigator blinded for Drosophila groups, who <1> calculated the 
ratio of area positive for myolysis (areas with > 10% loss of sarcomeres) compared to 
total area, using ImagePro software (29); and <2> scored mitochondrial degeneration by 
determining the ratio degenerated versus total mitochondria. 
Calpain activity measurement 
Early Drosophila pupae were lysed in a non-denaturing buffer (CelLytic™ MT Cell Lysis 
Reagent, Sigma, The Netherlands). Protein concentration was determined by using 
Bio-Rad Protein Assay Kit (Bio-Rad, USA). DABCYL-Thr-Pro-Leu 
-Lys~Ser-Pro-Pro-Pro-Ser-Pro-Arg-EDANS (Calpain Substrate III, Fluorogenic, Merck, 
Germany) was used as a substrate for calpain. Hereto, protein extract (30 µg) was added 
to Cal pain Substrate III (60 µM final concentration) in 100 µl phosphate buffered saline. 
Fluorescence release was measured at 320-nm excitation/460-nm emission by 
fluorometry (SpectraMax Gemini XPS, Molecular Device, USA) after 90 min incubation 
at room temperature. 
Statistical analysis 
Results are expressed as mean± SEM. All  experimental procedures were performed in at 
least duplicate series. ANOVA was used for multiple-group comparisons. Student t tests 
were used for comparisons involving only 2 groups, and t tests with Bonferroni 
correction were used to compare individual group differences when multiple-comparison 
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ANOVA was significant. All P values were two-sided. P<0.05 was considered 
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Figure 1 Tachypacing of Drosophila induces heart wall remodeling, including gradual reduction in 
contractile function, induction in arrhythmic periods and reduction in heart wall shortening. A) Images 
of an early Drosophila pupae in systole and diastole. The heart wall is marked with an arrow. 8) 
I l lustrations of heart wall contractions are depicted after 2 hours normal pacing (2,2Hz) and 
tachypacing (5Hz) of early pupae of a WI  1 1 8 genetic background. 350 frames corresponds to 1 0  
seconds. C)  Rate of  heart wall contractions are depicted for  non paced, normal paced (2,2Hz) and 
tachypaced (3,4 and 5Hz) early pupae. D) Arrhythmicity index of non-paced, normal paced (2.2Hz) 
and tachypaced (3,4 and 5Hz) early pupae. E) Amplitude of heart wall shortening of normal paced 
(2,2Hz) or tachypaced (3,4 and 5Hz, 2 hours) wild-type early pupae. N=1 3-20 early pupae per 
condition. **  P<0.0 I vs Control normal paced, ** *P<0.00 1 vs Control normal paced. 
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Results 
Tachypacing of Drosophila induces contractile dysfunction in the heart wall. 
Early Drosophila pupae (Figure IA) possessed a basal rate of 2.2Hz ± 0.2Hz and were 
subjected to tachypacing at 3, 4 and 5 Hz for up to 2 hours. During interruption of 
tachypacing, the spontaneous contractile function of the heart wall was determined. It 
was found that tachypacing results in a gradual and significant reduction in heart 
contraction rate (Figure l B,C, supplementary information movie 1 and 2). In addition, 
tachypacing also induced a significant induction in arrhythmic episodes (Figure l B,D, 
supplementary information movie 3 and 4). Moreover, increasing frequency of 
tachypacing induced a gradual reduction in the amplitude of diastolic and systolic heart 
wall shortening (Figure IE). Since tachypacing at 5Hz, a 2.3 fold rate increase compared 
to basal heart rate, significantly induced contractile dysfunction of the heart wall, this 
setting was used in all following tachypacing experiments. 
Heat shock and the HSP-inducers GGA and BGP-15 increase HSP levels in 
Drosophila and protect against tachypacing-induced contractile dysfunction. 
In in vitro cardiomyocyte and in vivo canine models for AF, it was observed that 
HSP-inducing treatments protect against tachycardia remodeling ( 4,8). In order to 
determine if the same result can be obtained in tachypaced Drosophila, fly stocks were 
subjected to a heat treatment (1 hour 37°C, 16 hours recovery), or pretreatment with the 
HSP inducing agents GGA or BGP15 . Quantitative polymerase chain reaction with 
reverse transcription (RT-PCR) was used to determine the relative abundance of 
endogenous DmHSPs. All three HSP-inducing treatments effectively induced the heat 
shock response as evidenced by an increase in mRNA levels of endogenous 
DmHSP70AA and DmHSP27 (Figure 2A). 
All HSP inducing treatments protected against tachypacing-induced reduction in heart 
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contraction rate (Figure 2B), increase in arrhythmic episodes (Figure 2C) and reduction in 
amplitude of heart wall shortening (Figure 2D). These results indicate that boosting the 
heat shock response results in protection against tachypacing-induced contractile 
dysfunction of the heart in Drosophila pupae, thus further validating Drosophila as an in 
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Figure 2 HSP-inducing treatments protect against tachycardia remodeling in Drosophila. A) A mild 
heat shock (HS), GGA or BGP- 1 5  pretreatment induces the amount of mRNA of Drosophila 
DmHSP27 and DmHSP70AA compared to RpL32 levels as a standard, as determined by QPCR. B) 
The percentage of initial contraction rate is depicted for normal paced (NP) and tachypaced (TP) early 
W 1 1 1 8 pupae with or without HS, GGA or BGP- 1 5  pretreatment. C) Arrhythmicity index of normal 
paced (NP) and tachypaced (TP) early pupae with or without HS, GGA or BGP- 1 5  pretreatment. D) 
Degree of heart wall shortening of normal paced or tachypaced (2 hours) wild-type early pupae with 
or without HS, GGA or BGP- 1 5  pretreatment. N=l 5-20 early pupae per condition. ** P<0.01 vs 
Control, ***P<0.001 vs Control, # P<0.01 vs Control tachypaced. 
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DmHSP23 overexpression protects against tachypacing-induced contractile 
dysfunction and structural changes of the heart wall. 
Previously, we observed a protective effect of HSPB 1 ,  the most prominent heat inducible 
cytosolic member of the human family of small HSPs, against tachycardia remodeling in 
HL-I atrial cardiomyocytes ( 4 ). To further validate our model, it was tested if the 
cytosolic heat inducible member of the Drosophila family of small HSPs, DmHSP23 
(21,30), protects against tachycardia remodeling. Indeed, the DmHSP23 overexpressing 
transgenic strain (Table 1 )  was protected against tachypacing-induced reduction in heart 
contraction rate (Figure 3A,B, supplementary movie 3), increase in duration of 
arrhythmic episodes (Figure 3C) and also reductions m amplitude of heart wall 
shortening (Figure 5C). In addition, (ultra)structural evaluation of the heart wall indicates 
that tachypacing induces l oss of sarcomeres (myolysis, Figure 4A,B) and degeneration of 
the mitochondria (Figure 4A,C), including occasional enlargement and disorganization of 
cristae (Figure 4A). All these (ultra)structural changes were significantly attenuated in 
tachypaced DmHSP23 overexpressing Drosophila strain (Figure 4B,C). Previously, it 
was shown that induced calpain activity plays a molecular switch between the initial 
trigger for functional remodeling, calcium overload, and structural remodeling in 
experimental models for AF, but also in human AF (5 ,31 ). Therefore, calpain activity was 
measured in normal paced and tachypaced Drosophila. It was observed that tachypacing 
induces an increase in calpain activity, which was significantly attenuated in the 
DmHSP23 overexpressing Drosophila strain (Figure 4D). 
Unravelling the mechanism of DmHSP23 protection against tachycardia remodeling, 
by comparing small HSP overexpressing Drosophila strains. 
Having established that tachypacing of Drosophila results in contractile dysfunction, 
which can be prevented by general overexpression of HSPs and in particular DmHSP23, 
we next used a genetic approach to get more mechanistic insight in its mode of protection. 
I 1 8  
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Hereto, we used five Drosophila strains overexpressing different small HSPs with various 
cellular localization and functions in protein refolding, protein aggregation and autophagy 
(Table 1). Overexpression of DmCG4461, which lacks these functions, was also 
ineffective in protection against tachycardia remodeling (Figure 5 ). Next, it was tested 
whether the protective effect of DmHSP23 requires it cytosolic localization. Hereto, we 
used flies overexpressing DmHSP27, which is exclusively localized in the nucleus but 
otherwise shares most (functional) features of DmHSP23 (28,30,32-34). As can be seen 
in Figure 3B,C DmHSP27 did not result in protection against AF, indicating that a protein 
refolding activity in the nucleus is insufficient for the protective effect. Yet, 
overexpression of the DmCG7409, a cytosolic protein that has a strong activity to support 
protein refolding, did also not reveal tachycardia protection, suggesting that the 
remodeling induced by tachycardia cannot be prevented by the refolding-like activities of 
DmCG7409. Overexpression of DmHSP67Bc, which lacks this classical chaperone-like 
activity (Table I )  (25 ) but which induces autophagy and hereby assists in the clearance of 
toxic protein aggregates (24), also did not protect against tachycardia remodeling (Figure 
5 ). In addition, overexpression of (the non-heat inducible) DmCG14207, which enhances 
protein refolding (25 ) and associates with Z bands in muscles (35), did not protect against 
tachycardia remodeling (Figure 5 ). Overexpression of the small HSP of interest was 
confirmed by Western blot analysis (Figure 6). Thus, our findings suggest that the 
effectiveness of DmHSP23 to protect against tachycardia remodeling is due to a specific 
cytosolic feature related to tachycardia, which is unrelated to protein refolding or 
autophagic capacities, and can not be prevented or repaired by all other small HSP 
members. 
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Figure 3. DmHSP23 but not DmHSP27 overexpressing Drosophila are protected against tachycardia 
remodeling. A) Heart wall contractions are depicted for normal paced (NP) and tachypaced (TP, 2 
hours) early pupae with UAS-DmHSP23 genetic background (no DmHSP23 overexpression, UAS) 
and with a UAS-actinGAL4-DmHSP23 (DmHSP23) overexpressing background. B) The percentage 
of initial contraction rate is depicted of normal paced (NP) and tachypaced (TP) early pupae of control 
UAS, DmHSP23 and DmHSP27 overexpressing strains. C) Arrhythmicity index of normal paced (NP) 
and tachypaced (TP) early pupae of control UAS, DmHSP23 and DmHSP27 overexpressing strains. 
N=l 2-20 early pupae per condition. *P<0.05, ** P<0.0 1 vs Control, ***P<0.00 1 vs Control. 
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Figure 4 DmHSP23 overexpressing Drosophilas are protected against tachypacing-induced structural 
remodeling, including loss of sarcomeres (myolysis) and mitochondrial damage. A) Left panel shows 
light microscopic structure of the heart wall in normal paced and tachypaced control (UAS-DmHSP23) 
and DmHSP23 (UAS-actinGAL4-DmHSP23) overexpressing strains. Right panel shows electron 
microscopic details of the cardiomyocytes and mitochondria. Arrowheads show loss of sarcomeres in  
the heart wall and asterisk marks mitochondrial damage. B) Quantification of ratio myolysis compared 
to total area of sarcomeres and C) ratio degenerated mitochondria compared to total amount of 
mitochondria in normal paced and tachypaced control (UAS-DmHSP23) and DmHSP23 
(UAS-actinGAL4-DmHSP23) overexpressing strains. D) Tachypacing induces calpain activity, and 
DmHSP23 (UAS - actinGAL4 - DmHSP23) overexpressing strains were protected. N=3-5 early 
pupae per condition ** P<0.01 vs Control normal paced , # P<0.05 vs Control tachypaced. 
Figure 5 HSP67Bc, CG4461 ,  CG7409 and CG14207 show no protective effects against tachycardia 
remodeling in Drosophila. A) The percentage of initial contraction rate is depicted for normal paced 
(NP) and tachypaced (TP) early pupae of control Wl 1 18-actinGAL4 and UAS-actinGal4-HSP67Bc, 
-CG4461, -CG7409 or -CG14207 overexpressing strains. B) Arrhythmicity index ofnormal paced (NP) 
and tachypaced (TP) early pupae of control and HSP67Bc, CG4461 ,  CG7409 or CG14207 
overexpressing strains. C) Combined results of degree of heart wall shortening of normal paced or 
tachypaced (2 hours) early pupae of control and DmHSP23, DmHSP27, HSP67Bc, CG4461 ,  CG7409 
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Table 1 Overview of Drosophila melanogaster transgenic small HSP overexpressing lines used in the current study. Drosophila small HSP Classical sHSP Novel sHSPs 
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Figure 6 Western blot showing overexpression of the individual small DmHSPs in transgenic 
Drosophila strains. A) Representative blot showing overexpression of the classical Drosophila small 
HSPs, DmHSP23 (UAS-actinGAL4-DmHSP23) and DmHSP27 (UAS-actinGAL4-DmHSP27), 
compared to respectively control UAS-DmHSP23 or UAS-DmHSP27 genetic background. B) 
Representative blot showing overexpression of novel Drosophila small HSPs, 
UAS-actinGAL4-HSP67Bc, -CG446 1 ,  -CG7409 or -CG14207, compared to control 




Previously, we reported on cardioprotective effects of HSPs, especially the small human 
HSPB 1, and the HSP-inducing agent GGA against important features of tachycardia 
remodeling, such as electrical and structural remodeling and contractile dysfunction 
( 4,6-8). In the present study, we demonstrated for the first time that the protective effects 
are also observed in vivo in the Drosophila melanogaster model for tachypacing-induced 
contractile dysfunction of the heart wall. We observed that both HSP-inducing agents 
GGA and BGP-15 but also a heat shock pretreatment protect against tachypacing-induced 
contractile dysfunction. By comparing in transgenic Drosophila strains the 
overexpression of six individual small HSPs, it was found that only DmHSP23 resulted in 
cardioprotective effects. Moreover, our findings indicate that similar findings observed in 
in vitro tachypaced HL-1 and dog atrial cardiomyocytes and in vivo canine model for AF, 
Drosophila melanogaster can be used to study tachycardia remodeling. Since Drosophila 
can be easily utilized to manipulate gene expression in a highly precise spatial and 
temporal fashion, this model of AF thus seems to represent an excellent tool for studying 
molecular mechanisms of heat shock-mediated cardioprotection and genes involved in 
tachycardia remodeling and AF progression.  
Tachypaced Drosophila melanogaster as model system for contractile dysfunction of 
the heart wall. 
The Drosophila heart is a simple tube that runs along the dorsal midline of the pupae (36). 
The heart is composed of two major cell types: cardioblasts, which form the heart tube 
and are the contractile cells of the heart, and pericardia! cells, which flank the 
cardioblasts but do not express muscle proteins (36). Moreover, Drosophila myocardium 
contains myogenic cardiac pacemaker cells, which respond to a variety of 
neurotransmitters and hormones by adjusting heart rate (3 7). Tachypacing of the 
Drosophila heart induced contractile dysfunction of the heart wall that was comparable to 
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the remodeling observed in in vitro tachypaced cardiomyocytes (5 ,38), in vivo animal 
models for AF (39,40) and clinical AF ( 41,42). Moreover, the cardioprotective effect of 
the general induction of the heat shock response, that was previously shown to be 
protective in in vitro ( 4 ,6) and in vivo ( 4,8) AF models, was also found to be protective in 
the tachypaced Drosophila model. Finally, also overexpression of a single small HSP, 
DmHSP23, revealed the same cardioprotective effects as seen for human HSPB 1 in 
tachypaced HL-1 cardiomyocytes. Together, the data validate the tachypaced Drosophila 
model as versatile model system for tachycardia-induced heart wall remodeling and AF 
progression. 
Small heat shock proteins in Drosophila melanogaster 
The family of Drosophila melanogaster small HSPs comprises 12 proteins, but only four 
of them have been studied in greater detail and form the classical DmHSPs, DmHSP22, 
DmHSP23, DmHSP26 and DmHSP27 (25 ). Although these four proteins share high 
homology, their intracellular localization differs (25 ,30). DmHSP22 is localized to 
mitochondria ( 43), DmHSP23 and DmHSP26 were found in the cytosol (30,32) and 
DmHSP27 is present in the nucleus (33). It is unknown which member of the Drosophila 
small HSP family represents the functional ortholog of human HSPB 1. Based on the heat 
inducibility of HSPB 1, its cytoplasmic localization, and its ability to function in the 
HSPAIA dependent refolding activity, DmHSP23 and DmHSP26 most closely resemble 
HSPB 1 (25 ). DmHSP26 is, however, rather effective in protection against aggregation of 
polyglutamine proteins that are associated with neurodegenerative disease (30), a 
property that is lacking for DmHSP23 (30) and human HSPBl (44). Although we did not 
include flies overexpressing DmHSP26, we now show that DmHSP23, like HSPB 1, also 
protects against tachycardia remodeling. This finding suggests that DmHSP23 might 
represent a functional ortholog of human HSPBI. 
The question arised which small HSP activity is required for cardioprotection in AF. In a 1 25 
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recently completed study comparing all 1 0  human HSPB members in a HL-1 
cardiomyocyte model for AF ( 45), we found three members, HSPB 1 ,  HSPB6, and 
HSPB7, to strongly protect against tachycardia remodeling and one member, HSPB8, had 
minor protective actions. DmHSP67Bc was recently found to be the functional ortholog 
of the human HSPB8 (24), and was ineffective in the current study. This implies that the 
autophagy stimulating function of the human HSPB8 (24,46,47) and DmHSP67Bc (24) is 
insufficient to protect against tachycardia remodeling in Drosophila. The function shared 
by HSPB 1 ,  HSPB6, and HSPB7 that was found responsible for cardioprotection, was 
their ability to bind to actin and to prevent actin polymerization ( 45) and not their 
association with canonical activities of HSPBs like refolding of denatured proteins ( 45). 
Also in the current study, two cytosolic members of the Drosophila small HSP family that 
do function in refolding, CG7409 and CG1 4207, do not protect against tachycardia 
remodeling. This suggests that neither CG7409 nor CG 1 4207 are likely to be functional 
orthologs of HSPBI , HSPB6, or HSPB7. The same is true for CG4461 , for which no 
clear activity has been found so far. Finally, flies overexpressing DmHSP27, which is 
exclusively localized in the nucleus but otherwise shares most (functional) features of 
DmHSP23 (30) did not result in protection against tachycardia remodeling, indicating 
that cytoplasmic activity is required for a protective effect. Based on the studies with the 
human HSPB members ( 45 ), actin binding may be a key feature required for such 
cardioprotective activity. Whether DmHSP23 indeed can bind actin has not been 
demonstrated so far. Only for HSP67Bc and CG 1 4207, it was shown that they associate 
with Z bands in muscles (24,35)[22;32] ,  but neither one of these two members protected 
against tachycardia remodeling in Drosophila, indicating that this feature is not 
associated with the observed cardioprotective effect. Furthermore, it might be argued that 
the VS tag of the novel small HSPs is suppressing its function, but the HSP67Bc, 
CG1 4207 and CG7409 transgenic strains were found to be efficient in preventing 
aggregation of disease related misfolded proteins, indicating no functional interference of 
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the VS tag (25 ). Thus, the precise mechanism for the effectiveness of DmHSP23 to 
protect against tachycardia remodeling remains to be determined, but there are 
indications that a specific tachycardia-related feature of DmHSP23 that is not shared by 
the other five small DmHSP members, plays a key role. The combined data also 
demonstrate that, next to sharing common functions in proteostasis, small HSP seem to 
have distinct client specific functions. 
In summary, the tachypaced Drosophila model for AF as shown in the current study, 
provides a versatile system to study both mechanism of tachycardia remodeling and 
disease progression, to search for genetic modifiers of tachycardia remodeling, and to 
screen for pharmacological compounds that can prevent AF mediated cardiac damage. 
Supplementary materials related to this article can be found online at 
http: //www.sciencedirect.com/science/ai1ic1e/pi i/S0022282811002288 
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Chapter 6 
1. Central concepts of atrial remodeling 
Atrial fibrillation (AF) is the most common sustained clinical tachyarrhythmia and a 
significant contributor to cardiovascular morbidity and mortality ( 1 ). AF has the tendency 
to become more persistent over time (2 - 4). In addition, the longer the arrhythmia exists, 
successful pharmacological and electrical cardioversion, including the maintenance of 
sinus rhythm thereafter, is more difficult (3). Clinical observations show that immediately 
after cardioversion, atrial contractile function is severely impaired or even absent and 
recovery of contractile capacity is related to the preceding AF duration (1 ). 
Over the past decade, much research has focused on the dissection of mechanisms 
underlying the progressive nature of AF (1). An important recognition was that AF, once 
initiated, alters atrial electrophysiological properties in a manner that favors the induction 
and maintenance of AF (2). A conceptual model for the mechanisms underlying AF 
progression is depicted in Figure 1. During AF, atrial cardiomyocytes are subjected to 
very rapid (400 - 600 times per min) and irregular activation, causing an excess Ca2+ 
entry via the L-type Ca2+ channel into the myocytes (5 ). The resulting increase in 
intracellular Ca2+ causes inactivation of the L-type Ca2+ channel. As a result, the action 
potential shortens and contractile dysfunction develops, enhancing the likelihood of 
induction and maintenance of AF (6). 
A second mechanism of early remodeling consists of changes in the activity of specific 
kinases and phosphatases, resulting in the modulation of key intracellular proteins 
involved in Ca2+ handling. Chapter 4 revealed a prime role for tachypacing-induced 
RhoA GTPase activity and subsequent F-actin stress fiber formation and reduction in 
Ca2+ transient (CaT). Rho GTPases represent a family of small GTP-binding proteins 
involved in cytoskeletal organization, migration, transcription, and proliferation and have 
gained considerable recognition as powerful regulators of actin cytoskeletal organization 
in the heart (7). It has been recognized that active Rho GTPases stimulate the conversion 
of G-actin to F-actin, which results in cytoskeletal injury including changes in calcium 
signaling, disturbances in action potential conduction and contractile dysfunction, which 
1 34 
General Discussion and Future Perspectives 
are all substrates for the development of AF. Actin stress fiber assembly and contraction 
are predominantly mediated by Rho-associated serine/threonine kinase (ROCK), a major 
down-stream effector of the Rho pathway. Consistent with all of the above, we show that 
tachypacing activates RhoA and that inhibition of ROCK, its effector of actin 
polymerization, prevents tachypacing-induced reduction in CaT (Chapter 4). 
Meanwhile, by using in vitro models, it was also found that the tachypacing-induced 
decrease in L-type Ca2+ current can be mediated by activation of other key 
phosphorylation-regulating systems, potentially including CaMKII and calcineurin 
related pathways (8). Furthermore, indirect evidence suggests that AF-induced changes in 
the kinomic profile leads to de-phosphorylation of the L-type Ca2+ channel, and 
consequently in reduction of the L-type Ca2+ current (9,10). In addition, AF is associated 
with phosphorylation of phospholamban and ryanodine receptors (RyR2), which might 
endorse cellular Ca2+ overload (11,12). So it can be concluded that AF induces changes in 
the phosphorylation status of various proteins that are involved in atrial remodeling. 
When AF persists, structural remodeling of cardiac tissue will occur (13,14). This form of 
tissue adaptation resembles ischemic hibernation and is defined by the ability of the 
myocytes to turn into a non-functional phenotype by degradation of the myofibril 
structure (myolysis), which leads to contractile dysfunction (14 - 17). Cell viability will, 
however, be maintained for a prolonged period of time, thus ensuring tissue integrity (but 
not tissue functionality) (16). Consequently, myolysis is found in patients with persistent 
AF and not in patients who exclusively display paroxysmal forms of the arrhythmia (13), 
suggesting a role for myolysis in the promotion of remodeling. Previously, it was shown 
that the cysteine protease calpain represents an important switch between 
tachycardia-induced Ca2+ overload and atrial remodeling (13). Chapter 2 describes the 
first study to provide definite evidence for a main role of calpain in troponin degradation 
and dysfunction in both in vitro tachypaced HL-1 atrial cardiomyocytes and human tissue 
of patients with AF. Tachypacing of HL-1 cardiomyocytes induced a gradual and 
significant degradation of various cardiac troponins (cTnl , cTnT and cTnC) which was 
associated with contractile dysfunction. Both were prevented by inhibition of calpain but 
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not by inhibition of caspases or the proteasome. In cardiac tissue of patients with 
persistent AF, a significant degradation in cTnl, cTnT and cTnC was found, which was 
absent in cardiac tissue from patients with normal sinus rhythm or paroxysmal AF. 
Degradation of troponins in turn correlated significantly with both calpain activity and 
the amount of myolysis in the tissues. These results indicate that calpain activation 
represents a key factor underlying myofibrillar protein degradation, myolysis and 
contractil e dysfunction. Since myolysis and contractile dysfunction contribute to the AF 
substrate, tachypacing-induced calpain activation may relate to the self-perpetuating 
nature of AF. In addition, the activation of cysteine proteases is widely known to initiate 
and execute apoptosis (18). However, particularly in cardiac myocytes, apoptosis is 
generally not completed. i.e., no DNA fragmentation occurs and cells remain intact. 
Depending on the intensity of the stress, activation of cysteine proteases may result in 
atrial remodeling, by degradation of the L-type Ca2+ channel (19,20) or by cleavage of 
myofilament proteins such as cTnl , cTnT, cTnC (21-23), leading to shortening of action 
potential duration, myolysis and contractile dysfunction and hence persistency of AF 
(Figure 1 ). Interestingly, it was observed in Chapter 2 that caspases are activated as 
result of tachypacing. Since effective pan-caspase inhibition did not attenuate cardiac 
troponin degradation and contractil e dysfunction, their role in contractile-protein 
degradation seems of l ess impmiance. The results further indirectly support the idea that 
the molecular, cellular and functional events that contribute to AF progression do not 
include apoptosis. 
2. Drosophila melanogaster as a novel experimental model system for studying 
tachycardia-induced remodeling 
A versatile model system is crucial to study the mechanisms underlying AF-related atrial 
remodeling. Over the past decades, several animal models such as dog, goat, rabbit and 
sheep have been extensively used to explore underl ying mechanisms and potential 
treatment of AF (24). Due to the low speed and high cost, and difficulty in manipulating 
the genetics of these organisms, these in vivo models are not convenient for experimental 
manipulations and high-throughput screening. Recently several in vitro cell models, 
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including the tachypaced HL-1 atrial myocytes, have been applied to provide insights 
into the mechanisms underlying AF progression and development (Chapter 2 and 3, 25). 
In Chapter 5, we introduce a novel versatile in vivo model for tachycardia remodeling 
utilizing Drosophila melanogaster. Drosophila is one of the most popular invertebrate 
model organisms and has been used extensively in many areas of biological research, 
especially genetics and development (26). The application of this model is supported by 
the existence of functionally conserved features between Drosophila and humans, 
including cardiac aging and development of heart failure (27, 28). Combined with short 
life-cycle, cost efficiency, the powerful techniques for genetic and molecular 
manipulations, the Drosophila system is highly suitable for compound testing (29). In 
addition, Drosophila contains a pumping heart driven by a primary pacemaker located 
caudally in the heart from which the heart beat propagates interiorly as a wave of 
peristalsis (30). Based on these considerations, we started to subject flies at early pupae 
stages to tachypacing and found that their heart function significantly declines. 
Furthermore, an increase in calpain activity was found which related to structural 
remodeling, in the form of myolysis and mitochondrial damage. All these observations 
are in line with human and experimental AF (14,25 ). Finally, our tachypacing-induced 
Drosophila system was found to be applicable for chemical compound screening by 
using HSP-inducing drugs, such as GGA and BGP-15 (Chapter 5). 
3. HSPB family: intrinsic protection against tachypacing-induced atrial remodeling 
Since it has been generally recognized that heat shock proteins (HSPs) reveal protective 
roles against various forms of stress-induced cell damage (31), we investigated in 
Chapter 3 the role of various HSPs in AF by determining the expression levels of a 
number of key stress-inducible HSPs in atrial tissue of patients with paroxysmal and/or 
persistent AF. We found elevated HSPBl expression in atrial tissue from patients with 
paroxysmal AF compared with patients with persistent AF or sinus rhythm. This was 
confirmed in a subsequent study by Yang et al. (32), suggesting that the ability to 
up-regulate HSPB 1 may be crucial in attenuating the progressive nature of AF. 
Consistently, an inverse correlation was observed between HSPB I expression and the 
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duration of AF and the extent of myolysis (Chapter 3). It was therefore hypothesized 
that increased HSPB l expression levels limit the progression from paroxysmal to 
persistent AF. 
To test more directly whether HSPs indeed protect against AF promoting effects, the 
tachypaced HL-1 cell model for AF (Chapter 3) and our novel tachypaced Drosophila 
melanogaster model system were used (Chapter 5) (25,33). In the HL-1 atrial 
cardiomyocytes our group previously already observed that pre-induction of HSPs by a 
mild non-toxic heat shock or by the drug geranylgeranylacetone (GGA) prior to 
tachypacing prevented atrial remodeling, such as contractile dysfunction and structural 
remodeling (Chapter 3, 25 ). Consistently, orally administered GGA suppressed 
AF-related refractoriness abbreviation and AF promotion in dogs (25 ) and also protected 
from AF-related contractile dysfunction in flies (Chapter 5). 
Using the cel l model (25 , Chapter 3), we al ready demonstrated that this GOA-mediated 
protection required HSPB 1, but not HSPA 1 A, overexpression. Furthermore, these studies 
revealed that the single overexpression of HSPB I sufficed to protect AF-mediated 
myolysis. This is why we next tested which members of the small HSPB family show 
protective effects against AF progression and their mode of action. 
4. Mode of action of HSPBl and other HSPB members in AF 
In Chapter 4, we describe that in addition to HSPB I ,  also other members of the HSPB 
family (i.e. HSPB6, HSPB7 and HSPB8) display protective effects against 
tachypacing-induced remodeling. As several HSPB proteins can form hetero-oligomeric 
complexes with each other, we first tested whether their protective effect were merely in 
the context of supporting oligomeric structures of endogenous HSPB I or not. As 
downregulation of endogenous HSPB I did not impair the protective effects of HSPB6, 
HSPB7 and HSPB8, we concluded that their effects were independent of endogenous 
HSPB I. Interestingly, all the 4 protective HSPB members (but not the non-protective 
members) were able to reduce the formation of F-actin stress fibers, supporting the view 
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that actin protection is the key to the protective effects of HSPB members i n  AF. Yet, the 
mode of action in prevention of F-actin formation of the 4 different protective HSPB 
members seemed to differ. Whereas HSPB8 interfered with the upstream 
tachypacing-induced RhoA GTPase activitati on, HSPB 1, HSPB6, and HSPB7 did not. 
Rather, HSPB 1, HSPB6 and HSPB7 were found to directly inhibit G- to F-actin 
polymerization and/or stimulate depolymerization, indicating a protecti ve role against 
tachycardia remodeling downstream of RhoA GTPase activation (Figure 1). 
Although our data points to actin as a target for HSPB-mediated protection in AF, we do 
not wish to exclude alternative modes of actions, that even could act in parallel. Such 
additional mechanisms of protection from AF might involve the direct modulation of 
ion-channel function or modulation of specific kinases, resulting in the preservation of 
the L-type Ca2+ current. Previously, HSPs were implicated in the regulation of 
ion-channel function in heart and brain (39-42). Some HSPs were found to interact 
di rectly with ion-channels, such as HSPB5 with Na+ channels (42), H SPA 1 A with 
cardiac K+ channel hHERG (40), and voltage-gated Ca2+ channels (41). Yet, HSPB5 was 
not protective in our AF cell model, which makes this mode of action less likely. 
HSPBs also may affect several signaling cascades that are activated in AF. E.g., it has 
been demonstrated in brain epithelial cells that exogenous administration of HSPB I 
inhibi ted the ATP-sensitive and calcium-activated potassium channels (39). Interestingly, 
studies showed that HSPs, including phosphorylated HSPB I, link signal-transduction 
cascades to (ion-channel) function (41,43,44) and this might also apply for the protective 
effect observed against tachypacing-induced reduction in L-type Ca2+ current. Although 
we describe in Chapter 4 the modulatory action of HSPB8 on RhoA-GTP activity with 
subsequent inhibi tion of ROCK and F-actin formation, in general, the exact role of 
HSPBs in modulating the activation of kinases or phosphatases is unknown. HSPB I 
associates with certain (downstream) kinases, such as lkB kinase and c-Jun N-tenninal 
kinase (JNK), thereby suppressing activation of the transcription factor NF-kB (45 ,46). 
Interestingly, these kinases were reported to be modulated during AF (47,48). Finally, the 
protective HSPBs might prevent myocyte remodeling via inhibition of calpain. Although 
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no studies described the modulation of calpain by HSPB, HSPB l was found to modulate 
in vitro other cystein proteases such as caspase 3 ( 49). 
Thus, based on the current knowledge, the main target of preventing AF-induced atrial 
remodeling is via attenuation of F-actin fiber formation. Alternative mechanisms might 
include prevention of the activation of the cysteine protease calpain, and prevention of 
changes in kinomics. 
Having established that at least 4 HSPB members could protect against 
tachypacing-induced remodeling, we next tried to test whether this finding could also be 
translated to the in vivo si tuation. Hereto, we used the Drosophila melanogster model for 
AF that we developed (Chapter 5). In order to avoid cross-species related artifacts, we 
focused on the family of Drosophila melanogaster small I-ISP members. This family 
comprises of 1 2  proteins and for several of them transgenic fly lines were already 
available (DmHSP22, DmHSP23, DmHSP26 and DmHSP27 (50) and CG14207, 
Hsp67Bc (5 1 ). Our findings in Chapter 5 reveal that only DmHSP23 can protect against 
AF. This member likely represents a functional ortholog of the human HSPB 1 as it shares 
many of the features of HSPB l including chaperone activity (35 ,52 ,53), dynamic 
oligomerization in phosphorylation dependent manner (53), cytoskeletal protection (53, 
This thesis) and now also protection against AF (Chapter 5). Another member that we 
tested, DmHsp67Bc, was recently found to be a functional ortholog of the human HSPB8 
(54). Our finding that Hsp67Bc, unlike in vitro, did not protect against tachycardia 
remodeling in  Drosophila (Chapter 5) implies that the RhoA-GTP effects of HSPB8 
observed in vitro may be insufficient to yield full protection in vivo. In this respect, it is 
notewmihy that also in vitro HSPB8 was the weakest of all protective H SPB members in 
vitro (Chapter 3). We recently demonstrated that DmHsp67Bc also shares functional 
similarity with HSPB8 (not HSPB 1 )  in i ts capacity to stimulate autophagy (54). This 
either implies that the protective effect of overexpression of HSPB8 on 
tachypacing-induced remodeling in vitro (Chapter 4) is independent of i ts stimulatory 
effect on autophagy or that autophagy stimulation is insufficient to provide protection in 
vivo. 
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Most importantly, the data show that overexpression of small HSPs also protect in vivo 
against AF-induced structural and functional remodeling. This underscores boosting of 
HSPB expression as a novel therapeutic strategy to ameliorate progression of AF in 
humans. 
5. Exclusive protection against AF by Beat Shock Proteins 
HSPB family members do share common features in cell stabilization and survival, 
however, they are not expressed at equal levels in heart tissue. The HSPB members that 
show high basal expression in heart comprise of HSPB 1, HSPB5 ,  HSPB6, HSPB7 and 
HSPB8. Interestingly, as shown in Chapter 3 and Chapter 4, all of these ' cardiac' 
HSPB members (with the exception of HSPB5)  were found to protect against 
tachypacing-induced remodeling (Table 1 ), suggesting basal expression and protective 
effectiveness to be related. The possible rational behind this may be that their high basal 
expression level allows these HSPB members to exert an immediate cardioprotective 
effect in response to stress conditions, without any lag time necessary for protein 
synthesis. Although H SPB 1, HSPB6, HSPB7 and HSPB8 protect against 
tachypacing-induced remodeling, no general consensus is found with other (protective) 
effects, such as assisting in protein refolding, reducing aggregation of misfolded proteins 
and heat inducibility (55 )  (for overview see Table I ). The findings suggest a unique 
function shared exclusively by HSPB 1 ,  HSPB6, HSPB7 and HSPB8 and therefore we 
nicknamed this particular group of HSPB members the Beat Shock Proteins (56). 
6. Heat shock protein modulation as a novel therapeutic approach in Atrial 
Fibrillation 
So far, the efficacy of commonly used drugs on remodeling is limited, as L-type Ca2+ 
channel blockers, Na+/H� exchange inhibitor and an angiotensin-converting enzyme 
inhibitor are ineffective in preventing remodeling caused by prolonged (>24 h) periods of 
atrial tachycardia (57). Drugs with T-type Ca2+ channel blocking action, such as 
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mibefradil (58) and amiodarone (59) prevent atrial tachycardia remodeling, although both 
also have a wide range of other properties so that the precise mechanism for their 
beneficial effect is unclear. 
Interventions with anti-inflammatory and/or antioxidant compounds, such as 
glucocorticoids (60) and statins (61), prevent atrial remodeling and may have some 
efficacy in cl inical AF (62,63). Interestingly, these glucocorticoids and statins induce 
HSPB l phosphorylation and lead to elevated HSPBl expression (64,65), leaving open 
the possibility that the protective effect of these drugs is due to ( co-)induction of HSPB 1 
(Table 2). This supports the search for novel , preferably more specific HSP (co-)inducers 
as an anti-remodeling intervention in AF. The drug used in our studies, GGA, was 
original ly introduced as an anti-ulcer agent (66) (Table 2). GGA is a non-toxic acyclic 
isoprenoid compound with a retinoid skeleton that induces HSP synthesis in various 
tissues, including gastric mucosa, intestine, liver, myocardium, retina, and central 
nervous system (66,67,68). GGA induces HSP expression by enhancing the activity of 
heat shock transcription factor HSFl in cel ls undergoing (mild) stress (66,69). It  is not 
active in unstressed cel ls, meaning that it must be considered as a HSF-1 boosting (but 
not activating) agent (70). This, in fact, may be very advantageous as chronic 
overexpression of HSP in unstressed cel l s  may have unwanted side-effects (71, 72). In our 
hands, GGA was effective in elevating HSP levels and subsequent AF protection in cell 
models (Chapter 3), Dm Model (Chapter 5) as wel l as in dogs (25). This, in fact, 
provides sufficient basis for a cl inical trial with GGA to prevent AF, albeit that GGA 
biodistribution remains an issue for improvement. Studies to generate more potent GGA 
derivatives are therefore currently developed by Nyken BV. 
Besides GGA-related compounds, a number of hydroxylamine derivatives such as 
Bimoclomol and Arimoclomol are known to co-induce the expression of HSPs by 
prolonging the activation of the heat shock protein transcription factor HSF-1 (73,74) 
(Table 2). In Chapter 5, one of them BGP-15 ,  that already had been shown to protect 
heart cell s  from ischemia reperfusion injury (75), was also found to protect against the 
tachypacing induced reduction in heart rate and loss of heart contraction in Drosophila. 
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Both GGA and BG Pl 5 induced the expression of endogenous DmHSPs (DmHSP70AA 
and DmHSP27). 
Together, our studies clearly reveal the potential of HSP boosting drugs in AF and urge 
for further testing in the prevention of experimental AF, and ultimately in patients with 
AF. 
7. Summary and Future perspectives 
New strategies for the management of AF will depend on a better understanding of the 
mechanisms underlying AF. Over the past 10 to 1 5  years, an increased awareness of the 
role  of "atrial remodeling" has substantially advanced the understanding of AF 
pathophysiology. In brief, the high rate of myocyte activation during AF causes cellular 
stress and hence activates the atrial remodeling processes, which paradoxical ly  promote 
persistency of AF. Atrial remodeling is brought about by an interplay of various changes 
in cel lul ar physiology, which favor (re)-occurrence or maintenance of AF. Further work 
is needed to more precisely unravel the molecular basis of atrial remodeling, particularly 
to enable exploitation of their therapeutic potential in the management of AF. 
This thesis provides strong indications, both from in vitro and in vivo models, that HSPs 
and in particular the beat shock proteins suppress atrial remodeling and the promotion of 
AF induced by tachyarrhythmia. Utilization ofHSPs offers a novel therapeutic strategy in 
AF, directed at maintaining or restoring tissue integrity and contractile function. 
Dissection of the molecular mechanism by which HSPs protects myocytes from 
remodeling may disclose more specific therapeutic interventions. Ultimately, inducers of 
HSPs may add to the therapeutic a1mament to delay progression towards persistent AF 
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Species Name Assisting Reducing Protecting against Heat 
refolding of aggregation of tachypacing-red need inducibili 
(heat) misfolded remodeling 
denatured proteins 
proteins 
HSPB I +++ --- +++ +++ 
HSPB2 -- --- --- ---
HSPB3 --- --- --- ---
HSPB4 +++ +-- --- ---
Homo sapiens HSPB5 
+++ --- --- +++ 
HSPB6 +- +-- +++ ---
HSPB7 --- +++ +++ ---
HSPB8 --- +-- ++- +++ 
HSPB9 --- +++ --- ---
HSPB I O  --- --- --- ---
HSP23 +++ +- +++ +++ 
HSP26 +++ +-- ??? +++ 
HSP27 +++ --- --- +++ 
HSP67BA --- --- ??? ++-
Drosophila HSP67BC --- +++ --- +++ 
melanogaster L2EFL +- --- ??? +++ 
CG446 1 --- --- --- +++ 
CG7409 +++ +-- --- ++-
CGI 3 1 33 --- --- ??? ++-
CG I4207 +++ -- --- ---
Table 1 Summarized characteristics and activities for human and Drosophila small HSPs 
ComQound Indications Target 
Geranylgeranhylacetone Atrial fibrillation HspB I 
lschaemic heart diseases HspA I A  
Dexamethasone Ischaemic heart diseases HSF- 1 
Atorvastatin Ischaemic heart diseases HspB I -Phosphorylation 
Bimoclomol Ischaemic heart diseases HspAIA  
C�closQorine A lschaemic heart diseases HsQAIA  
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Boezemfibrilleren is een hardnekkige hartritmestoornis, die leidt tot een sterke toename 
van het aantal samentrekkingen per tijdseenheid in de boezem spiercellen 
( cardiomyocyten). De ritmestoornis gaat gepaard met een duidelijk verhoogde kans op 
het ontwikkelen van andere (hart)ziekten. Verder is boezemfibrilleren een progressieve 
aandoening, waardoor veel patienten die beginnen met af en toe periodes met 
boezemfibrilleren (paroxysmaal boezemfibrilleren) later continu, chronisch 
boezemfibrilleren zullen krijgen. Daarnaast is de kans op een succesvolle cardioversie, 
bet weer terug brengen in het normale hartritme, in patienten met chronisch 
boezemfibrilleren kleiner dan in paroxysmaal boezemfibrilleren. Dit komt doordat de 
normale functie van de spiercellen in de boezem na cardioversie zich niet hersteld. De 
onderliggende oorzaak hiervan zijn veranderingen in de elektrische en structurele 
opbouw van de spiercellen (cardiomyocyt). Al deze veranderingen samen noemen we 
cardiomyocyt remodellering. 
Wat gebeurd er precies als boezemfibrilleren ontstaat? Door de verhoogde elektrische 
activatie van de boezem neemt de cardiomyocyt calcium op in de eel via het L-type 
calcium kanaal. Het verhoogde calcium niveau in de cardiomyocyt is schadelijk en de 
myocyt reageert hierop door de stroom door het L-type calcium kanaal te verminderen, 
waardoor er elektrische veranderingen ontstaan. Daamaast zorgt de toename in calcium 
ervoor <lat er eiwitafbrekende enzymen (proteases) geactiveerd warden. We hebben in het 
verleden al aangetoond <lat patienten met chronisch boezemfibrilleren meer actief 
calpaYne (een calcium-gereguleerde protease) in de cardiomyocyt hebben. Het verhoogde 
calpaYne zou in patienten ervoor kunnen zorgen <lat de spiereiwitten warden afgebroken, 
waardoor structurele remodellering en stoomissen in het samentrekken van de 
cardiomyocyt ontstaat. In hoofdstuk 2 wordt aangetoond <lat <lit inderdaad gebeurd in 
ons in vitro boezemmyocyten model voor boezemfibrilleren. Er vindt afbraak plaats van 
eiwitten betrokken bij de samentrekking (contractie) van cardiomyocyten: de cardiale 
troponines C, I en T. Door het boezemfibrilleren worden deze eiwitten afgebroken en 
remmers van calpaYne voorkomen deze afbraak. Remmers die werken op deze troponines, 
konden deze afbraak en contractiele dysfunction verhinderen terwijl remmers van 
andere proteases (het proteasoom of caspases) niet werkzaam waren. In patienten met 
chronisch boezemfibrilleren is ook eenzelfde afuame in cardiale troponines te zien, en 
deze afname correleert met een toename in calpaYne activiteit. Deze bevindingen geven 
aan <lat boezemfibrilleren calpaYnes activeren, die zorgen voor de afbraak van contraciele 
eiwitten, cardiale troponines. Vermindering in contractiele eiwitten kan weer leiden tot de 
hardnekkigheid van boezemfibrilleren. 
Doordat boezemfibrilleren een stress reactie veroorzaakt in de boezemmyocyt, hebben 
we in hoofdstuk 3 gekeken of er ook beschermende eiwitten tot expressie warden 
gebracht in boezemfibrilleren. Een belangrijke klasse beschermende eiwitten zijn de 
zogenaamde heat shock proteYnen (HSP). HSP helpen in de vouwing van nieuwe 
eiwitten, maar beschermen ook de door stress gedeeltelijk ontvouwde eiwitten. HSP 
vormen een centraal onderdeel van het eiwitkwaliteitscontrole systeem van de eel, <lat 
zorg draagt voor een juiste eiwithomeostase, ook wel proteostase genoemd. We hebben 
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gevonden dat patienten met paroxysmaal boezemfibrilleren een verhoogde expressie 
hebben van HSP27 (HSPB 1) en deze verhoogde expressie neemt af naarmate de patient 
!anger chronisch boezemfibrilleren heeft. Deze bevindingen suggereren dat 
boezemfibrilleren initieel een beschermende HSP reactie geven maar dat door uitputting 
van de HSP reactie boezemfibrilleren chronischer en hardnekkiger wordt. Inductie van 
HSP expressie kan dan beschermend werken, zoals we eerder aantoonden voor HSPB 1. 
Andere HSPs, zoals HSP70 (HSPAIA), hadden geen beschermende effecten. 
Omdat HSPB 1 een eiwit is uit de familie van kleine HSPs, hebben we onderzocht of 
andere !eden van deze familie eenzelfde beschermend effect hebben (hoofdstuk 4). In het 
in vitro model voor boezemfibrilleren bleek dat naast HSPB 1, ook HSPB6, HSPB7 en 
HSPB8 een beschermend effect hebben. Omdat al deze HSPs binden aan het netwerk van 
actine, l ijkt het erop dat hun beschermende effect in boezemfibrilleren te wijten is aan het 
voorkomen van veranderingen in dit netwerk. Actine speelt een belangrijke rol in de 
structuur en contractiele functie van de cardiomyocyt. Vanuit de literatuur is ook bekend 
dat RhoA-GTPases het netwerk van actine kan veranderen. Om te onderzoeken of dat 
ook in ons model het geval is hebben wij eerst de activiteit van RhoA GTPases gemeten 
tijdens boezemfibrilleren. We vonden een stapsgewijze toename in actief RhoA-GTPase 
tijdens boezemfibrilleren, die gepaard ging met de vorming van zogenaamde actine stress 
bundels en afname van contractiele functie. Overexpressie van HSPBI, HSPB6, HSPB7 
en HSPB8 verminderde het aantal stress bundels. Bovendien suggereren experimenten 
met geisoleerd actine dat HSPBl, HSPB6 en HSPB7 dit doen door directe binding aan 
het actine. HSPB8 daarentegen remde de stress bundel formatie door de activiteit van 
RhA-GTPase te verminderen. 
Bovengenoemde resultaten zijn verkregen gebruikmakend van een in vitro celmodel voor 
boezemfibrilleren. Om de vertaalslag te maken naar de in vivo situatie hebben wij een 
uniek fruitvlieg model voor boezemfibrilleren ontwikkeld (hoofdstuk 5). Een belangrijk 
voordeel van de fruitvlieg is de mogelijk tot genetisch manipuleren, snelheid van het 
opkweken van vliegen en de lage kosten. Wij hebben het hart van transparante larven van 
de fruitvlieg onderworpen aan snelle elektrische stimulaties. De l arven ontwikkelen dan 
contractiele dysfunctie en hebben een verhoogde kans op ritmestoomissen. Ook vonden 
we structurele remodellering in de vorm van afbraak van contractiele eiwitten en activatie 
van calparnes. Wanneer de larven voorbehandeld werden met HSP-inducerende 
geneesmiddelen, traden al deze remodelleringen niet op. Vervolgens hebben we 
transgene vliegen gekweekt die specifieke eiwitten uit de Drosophila (Dm) familie van 
kleine HSP tot expressie brachten in het hart. Van al de kleine HSP was alleen DmHSP23 
beschermend tegen remodellering. DmHSP23 is waarschijnlijk een functionele ortholoog 
van humaan HSP27. Het onderzoek in de fruitvlieg toont aan dat de fruitvlieg een 
uitstekend modelsysteem is voor onderzoek naar remodellering gernduceerd door 
boezemfibrilleren. Dit systeem biedt vele mogelijkheden om het expressieniveau van 
allerlei eiwitten te manipuleren om zo hun effect op remodellering te bestuderen. 
Samengevat toont het onderzoek dat remodellering van boezemspiercellen tijdens 
boezemfibrilleren verloopt via de activatie van RhoA-GTPases, stress bundel formatie en 
calpaYne activatie. Deze schadeprocessen kunnen warden voorkomen door de inductie 
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van HSP, waarbij specifieke leden van de kleine HSP familie erg effectief zijn. Dezelfde resultaten werden behaald in de gestimuleerde fruitvlieglarve. Enerzijds is daarmee een nuttig, nieuw modelsysteem voor atriumfibrilleren ontwikkeld; anderzijds toont het de brede toepassing van het HSP systeem in remodelering van het hart aan. Bovendien suggereren de resultaten dat nieuwe geneesmiddelen die zorgen voor de inductie van HSPs, zoals bijvoorbeeld geranylgeranylacetone (GGA), klinisch erg bruikbaar kunnen zijn door het behoud van boezemfunctie na cardioversie. Daamaast kan de opgedane kennis ook gebruikt worden voor andere hartaandoeningen die ook gepaard gaan met ( emstige) structurele remodellering. 
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